  Page i 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  
 
 
 
 
 
BARCONA Trial: A phase II/III, randomized, double -blind, placebo -
controlled, multi -center study of the effects of bardoxolone methyl in 
participants with SARS -Corona Virus -2 (COVID -19) 
 
Principal Investigator:  
 [INVESTIGATOR_342589], MD, MHA  
Department of Medicine  
Division of Cardiology  
 
[LOCATION_001] University Langone Health,  
[ADDRESS_424325], SKI 9R -109 
[LOCATION_001], NY [ZIP_CODE]  
[EMAIL_6642]  
[PHONE_7134]  
 
NYULMC Study Number:  S20-[ZIP_CODE]  
Funding Sponsor:  Reata Pharmaceuticals, Inc.   
[ADDRESS_424326], Plano, TX  
(972) 865 -2219  
 
IND Number:  150943  
Regulatory Sponsor :  Sripal Banga lore, MD, MHA  
Department of Medicine  
Division of Cardiology  
 
[LOCATION_001] University Langone Health,  
[ADDRESS_424327] nue, SKI 9R -109 
[LOCATION_001], NY [ZIP_CODE]  
[EMAIL_6642]  
[PHONE_7134]  
 
Study Product:  Bardoxolone methyl  
Study Product Provider:  Reata Pharmaceuticals, Inc.  
ClinicalTrials.gov 
Number                 [STUDY_ID_REMOVED]  
 
Protocol Version: 1. 1 
Version Date:  September 9 , 2020
 

Study number:  S20-[ZIP_CODE]   Page ii 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Statement of Compliance  
 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection of 
Human Subjects (45 CFR Part 46), 21 CFR Parts 50, 56, 312, and 812 as applicable, any other applicable 
US govern ment research regulations, and institutional research policies and procedures. The International 
Conference on Harmonisation (“ICH”) Guideline for Good Clinical Practice (“GCP”) (sometimes referred to 
as “ICH -GCP” or “E6”) will be applied only to the exten t that it is compatible with FDA and DHHS regulations.  
The Principal Investigator [INVESTIGATOR_7433], or changes to the protocol will take place 
without prior agreement from the sponsor and documented approval from the Institutional Review Board 
(IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel 
involved in the conduct of this study have completed Human Subjects Protection Training.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study number:  S20-[ZIP_CODE]   Page iii 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019   
Protocol  Signature  [CONTACT_342679]: A phase II/III, randomized, double -blind, placebo -controlled, multi -center study 
of the effects of bardoxolone methyl in participants with SARS -Corona Virus -2 (COVID -19) 
 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection of 
Human Subjects (45 CFR Part 46), 21 CFR Parts 50, 56, 312, and 812 as applicable, any other applicable 
US government research regulations, and institutional research policies and procedur es. The International 
Conference on Harmonisation (“ICH”) Guideline for Good Clinical Practice (“GCP”) (sometimes referred to 
as “ICH -GCP” or “E6”) will be applied only to the extent that it is compatible with FDA and DHHS regulations. 
The Principal Invest igator will assure that no deviation from, or changes to the protocol will take place 
without prior agreement from the sponsor and documented approval from the Institutional Review Board 
(IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel 
involved in the conduct of this study have completed Human Subjects Protection Training.  
 
 
 
Version  Date:   September 9 , 2020  
 
 
 
 
 
Signature  [CONTACT_138358]  [INVESTIGATOR_342590]  (City,  Country)  
 
 
 
 
 
 
 
 
 
Study number:  S20-[ZIP_CODE]   Page iv 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_424328] OF ABBREVIATIONS  ................................ ................................ ................................ .......................  VII 
PROTOCOL SUMMARY  ................................ ................................ ................................ ...............................  1 
SCHEMATIC OF STUDY DESIGN FOR PHASE II AND PHASE III  ................................ ............................  7 
1 KEY ROLES  ................................ ................................ ................................ ................................ .......... 8 
2 INTRODUCTION, BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  .......................  9 
2.1 BACKGROUND INFORMATION AND RELEVANT LITERATURE  ................................ ................................  9 
2.2 NAME [CONTACT_33914]  ................................ .............................  10 
2.2.1  Preclinical Data  ................................ ................................ ................................ ......................  10 
2.2.2  Clinical Data to Date  ................................ ................................ ................................ ..............  11 
2.2.3  Dose Rationale (if applicable)  ................................ ................................ ................................  11 
2.3 RATIONALE  ................................ ................................ ................................ ................................ ... 11 
2.4 POTENTIAL RISKS & BENEFITS  ................................ ................................ ................................ ...... 12 
2.4.1  Known Potential Risks  ................................ ................................ ................................ ...........  12 
2.4.2  Known Potential Benefits  ................................ ................................ ................................ ....... 13 
3 OBJECTIVES AND PURPOSE  ................................ ................................ ................................ .......... 14 
3.1 PHASE 2 ................................ ................................ ................................ ................................ ....... 14 
3.1.1  Primary Objective  ................................ ................................ ................................ ...................  14 
3.2 PHASE 3 ................................ ................................ ................................ ................................ ....... 14 
3.2.1  Primary Objectives  ................................ ................................ ................................ .................  14 
3.2.2  SECONDARY AND EXPLORATORY OBJECTIVES  ................................ ................................ ....................  14 
3.2.3.  SAFETY ENDPOINTS  ................................ ................................ ................................ .........................  14 
4 STUDY DESIGN AND ENDPOINTS  ................................ ................................ ................................ .. 15 
4.1 DESCRIPTION OF STUDY DESIGN  ................................ ................................ ................................ ... 15 
4.2 STUDY ENDPOINTS  ................................ ................................ ................................ .......................  15 
4.2.1  Phase 2  ................................ ................................ ................................ ................................ .. 15 
4.2.2  Phase 3  ................................ ................................ ................................ ................................ .. 16 
5 STUDY ENROLLMENT AND WITHDRAWAL  ................................ ................................ ...................  16 
5.1 INCLUSION CRITERIA  ................................ ................................ ................................ .....................  16 
5.2 EXCLUSION CRITERIA  ................................ ................................ ................................ ....................  17 
5.3 VULNERABLE SUBJECTS  ................................ ................................ ................................ ................  17 
5.4 STRATEGIES FOR RECRUITMENT AND RETENTION  ................................ ................................ ..........  18 
5.5 DURATION OF STUDY PARTICIPATION  ................................ ................................ .............................  18 
5.6 TOTAL NUMBER OF PARTICIPANTS AND SITES ................................ ................................ ................  18 
5.7 PARTICIPANT TREATMENT DISCONTINUATION  ................................ ................................ .................  18 
5.7.1  Reasons for Treatment Discontinuation  ................................ ................................ ................  18 
5.8 PARTICIPANT WITHDRAW AL OR TERMINATION  ................................ ................................ ................  18 
5.8.1  Reasons for Withdrawal or Termination  ................................ ................................ ................  18 
5.8.2  Handling of Participant Withdrawals or Termination  ................................ ..............................  19 
5.9 PREMATURE TERMINATION OR SUSPENSION OF STUDY  ................................ ................................ .. 19 
6 STUDY AGENT ................................ ................................ ................................ ................................ ... 19 
6.1 STUDY AGENT (S) AND CONTROL DESCRIPTION  ................................ ................................ ..............  [ADDRESS_424329] Storage and Stability  ................................ ................................ ................................  21 
Study number:  S20-[ZIP_CODE]   Page v 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  6.1.4  Preparation  ................................ ................................ ................................ .............................  21 
6.1.5  Dosing and Administration  ................................ ................................ ................................ ..... 21 
6.1.6  Route of Administration  ................................ ................................ ................................ ..........  21 
6.1.7  Starting Dose ................................ ................................ ................................ ..........................  21 
6.1.8  Dose Adjustments/Modifications/Delays  ................................ ................................ ................  21 
6.1.9  Duration of Therap y ................................ ................................ ................................ ...............  21 
6.1.10  Tracking of Dose  ................................ ................................ ................................ ................  21 
6.2 STUDY AGENT ACCOUNTABILITY PROCEDURES  ................................ ................................ ..............  21 
7 STUDY PROCEDURES AND SCHEDULE  ................................ ................................ ........................  22 
7.1 STUDY PROCEDURES /EVALUATIONS  ................................ ................................ ..............................  [ADDRESS_424330] of Care Study Procedures  ................................ ................................ ......................  24 
7.2 STUDY SCHEDULE  ................................ ................................ ................................ ........................  24 
7.2.1  Screening/Enrollment  ................................ ................................ ................................ .............  24 
7.2.2  Intermediate Visits  ................................ ................................ ................................ ..................  24 
7.2.3  Final Safety Follow -up................................ ................................ ................................ ............  26 
7.2.4  Withdrawal/Early Termination Visit  ................................ ................................ ........................  26 
CONCOMITANT MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................ ................................ . 27 
7.3 JUSTIFICATION FOR SENSITIVE PROCEDURES  ................................ ................................ .................  27 
7.3.1  Precautionary Medications, Treatments, and Procedures  ................................ .....................  27 
7.4 PROHIBITED MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................ ........................  27 
8 ASSESSMENT OF SAFETY  ................................ ................................ ................................ ..............  27 
8.1 SPECIFICATION OF SAFETY PARAMETERS  ................................ ................................ ......................  27 
8.1.1  Definition of Adverse Events (AE) ................................ ................................ ..........................  27 
8.1.2  Definition of Serious Adverse Events (SAE)  ................................ ................................ ..........  28 
8.1.3  Definition o f Unanticipated Problems (UP)  ................................ ................................ ............  28 
8.2 CLASSIFICATION OF AN ADVERSE EVENT ................................ ................................ ........................  28 
8.2.1  Severity of Event  ................................ ................................ ................................ ....................  28 
8.2.2  Relationship to Study Agent  ................................ ................................ ................................ ... 29 
8.2.3  Expectedness  ................................ ................................ ................................ .........................  29 
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP ................................ .... 29 
8.4 REPORTING PROCEDURES – NOTIFYING THE IRB ................................ ................................ ...........  30 
8.4.1  Serious Adverse Event Reporting  ................................ ................................ ..........................  30 
8.4.2  Unanticipated Problem Reporting  ................................ ................................ ..........................  30 
8.4.3  Reporting of P regnancy  ................................ ................................ ................................ .........  30 
8.5 REPORTING PROCEDURES – NOTIFYING THE STUDY SPONSOR  ................................ .......................  31 
8.6 REPORTING PROCEDURES – NOTIFYING THE FDA................................ ................................ ..........  32 
8.7 SAFETY OVERSIGHT  ................................ ................................ ................................ ......................  33 
9 CLINICAL MONITORING  ................................ ................................ ................................ ...................  33 
10 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ... 33 
10.1  STATISTICAL AND ANALYTICAL PLANS (SAP)  ................................ ................................ ..................  33 
10.2  STATISTICAL HYPOTHESES  ................................ ................................ ................................ ............  34 
10.2.1  Phase 2  ................................ ................................ ................................ ..............................  34 
10.2.2  Phase 3  ................................ ................................ ................................ ..............................  34 
10.3  ANALYSIS POPULATIONS  ................................ ................................ ................................ ...............  34 
10.4  DESCRIPTION OF STATISTICAL METHODS  ................................ ................................ .......................  34 
10.4.1  General Approach  ................................ ................................ ................................ ..............  34 
10.4.2  Analysis of the Phase 3 Primary Efficacy Endpoint ................................ ...........................  34 
10.4.3  Analysis of the Secondary/Explora tory Endpoints ................................ .............................  35 
10.4.4  Safety Analyses  ................................ ................................ ................................ .................  35 
10.4.5  Adherence and Retenti on Analyses  ................................ ................................ ..................  35 
10.4.6  Baseline Descriptive Statistics  ................................ ................................ ...........................  35 
10.4.7  Planned Interim Analysis  ................................ ................................ ................................ ... 35 
Study number:  S20-[ZIP_CODE]   Page vi 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  10.4.8  Additional Sub -Group Analyses  ................................ ................................ .........................  35 
10.4.9 Multiple Comparison/Multiplicity  ................................ ................................ ........................  36 
10.4.10  Tabulation of Individual Response Data  ................................ ................................ ............  36 
10.4.11  Exploratory Analyses  ................................ ................................ ................................ .........  36 
10.5  SAMPLE SIZE ................................ ................................ ................................ ................................  36 
10.6  MEASURES TO MINIMIZE BIAS ................................ ................................ ................................ ........  37 
10.6.1  Enrollment/Randomization/Masking Procedures  ................................ ..............................  37 
10.6.2  Breaking the Study Blind/Participant Code  ................................ ................................ ....... 37 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ................................ . 37 
12 QUALITY ASSURANCE AND QUALITY CONTROL  ................................ ................................ ........ 38 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................ ................................ ............. [ADDRESS_424331] POLICY  ................................ ................................ ................................ ... 41 
18 REFERENCES  ................................ ................................ ................................ ................................ .... 43 
19 SCHEDULE OF EVENTS  ................................ ................................ ................................ ...................  48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Study number:  S20-[ZIP_CODE]   Page vii 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_424332] Aspartate aminotransferase  
BNP B-type natriuretic peptide  
BUN Blood urea nitrogen  
CCC Clinical Coordination Center  
CFR Code of Federal Regulations (US)  
CGI-I Clinical Global Impression - Improvement  
CK Creatine kinase  
CKD Chronic kidney disease  
CKD-EPI [INVESTIGATOR_342591]-[ADDRESS_424333]  
FDA Food and Drug Administration (US)  
Study number:  S20-[ZIP_CODE]   Page viii 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_424334]  
IWRS Interactive Web Response System  
Keap1 Kelch-like ECH associated protein -1 
LAR Legally Authorized Representative  
LDH Lactate dehydrogenase  
LVEF Left ventricular ejection fraction 
MRI Magnetic resonance imaging  
NF-κB Nuclear factor kappa -light-chain-enhancer of activated B -cells 
Nrf2 Nuclear factor (erythroid -derived 2) -related factor [ADDRESS_424335] Upper limit of normal  
UP Unanticipated Problem  
US [LOCATION_002]  
WHO World Health Organization  
WOCBP Women of child bearing potential  
 
 
Study number:  S20-[ZIP_CODE]   Page 1 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Protocol Summary  
Title BARCONA Trial: A phase II/III, randomized, double -blind, placebo -
controlled, multi -center study of the effects of bardoxolone methyl in 
participants with SARS -Corona Virus -2 (COVID -19) 
Short Title  BARCONA Trial: A Randomized Trial of Bardoxolone Methyl in Patients 
Infected with SARS -Corona Virus -2 (COVID -19) 
Brief Summary  This multi -center, double -blind, placebo -controlled, randomized Phase 
2/3 trial will study the safety, tolerability, and efficacy of bardoxolone 
methyl in approximately 400 -440 patients hospi[INVESTIGATOR_342592] -19.  The Phase 2 portion of the trial will include approximately 
40 patients and is designe d to provide an early interim analysis of 
safety . The Phase 3 portion of the  trial will include approximately 360-
400 additional patients , and  is designed to determine wh ether 
bardoxolone methyl increases the probability of recovery at Day 29 
when compared with matching placebo.  Patients will be randomized 
using permuted block randomization  in a 1:1 fashion to either once -daily 
administration of bardoxolone methyl (20 mg) or matching placebo and 
treatment will be administered for the duration of hospi[INVESTIGATOR_059] (until 
recovery), with a maximum treatment duration of 29 days . 
Phase Phase s 2/3 
Objectives  Phase 2  
Primary : To provide an initial  assess ment of  the safety of bardoxolone 
meth yl in COVID -19 patients when compared with matching placebo  
Phase 3  
Primary:  To determine whether bardoxolone methyl in COVID -19 
patients increases  the probability  of recovery  at Day 29 when compared 
with matching placebo.  To assess the safety of bardoxolone methyl in 
COVID -19 patients when compared with matching placebo  
Secondary  and Exploratory : To assess the effect of bardoxolone 
methyl on other endpoints including renal function when compared with 
matching placebo.  
Study number:  S20-[ZIP_CODE]   Page 2 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Methodology  This multi -center, double -blind, placebo -controlled, randomized Phase 
2/3 trial will study the safety, tolerability, and efficacy of bardoxolone 
methyl in approximately 400 -440 patients hospi[INVESTIGATOR_342592] -19.  Phase 2 has safety as the prima ry endpoint and 
approximately 40 patients will be enrolled.  A pause in enrollment will 
occur until the DSMB performs an initial safety assessment  of Phase 2.  
Phase 3 is desi gned to determine whether bardoxolone methyl 
increases the probability of recovery  at Day 29  compared with mat ching 
placebo. In phase 3, approximately additional 360 -400 patients will be 
enrolled . Patients will be randomized using permuted block  
randomization in a 1:1 fashion to either once -daily administration of 
bardoxolone methyl (20 mg) or matching placebo.  Patients will be 
stratified by [CONTACT_342622] (i.e., 
mechanical ventilation with endotracheal intubati on) use at baseline 
(yes or no).  Enrollment of patients ≥70 years of age may be limited 
(e.g., comprise no more than 10% of all randomized patients) , pending 
safety review by [CONTACT_342623] .  Treatment will 
be administered for the durati on of hospi[INVESTIGATOR_059] (until recovery), with 
an expected duration of 10 days . For patients  who are hospi[INVESTIGATOR_222268] 10 days , treatment can be continued for a maximum 
treatment duration of 29 days .  Dose de -escalation (down to 10 mg) is 
permitted during the study if indicated clinically, and subsequent dose 
re-escalation is also permitted.   
 
Patients in the Phase [ADDRESS_424336]’s abilit y to return to the site for the visit. In this 
case, the visit may be performed by [CONTACT_648] . An independent Data and 
Safety Monitoring Board will advise the study leadership on safety 
aspects and overall progress of the study.  
Study number:  S20-[ZIP_CODE]   Page 3 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Endpoint s Phase 2  
Primary:  
• Safety (e.g., frequency , intensity, and relationship to study drug 
of serious adverse events [including unexpected deaths ], 
change from baseline in vital sign  and laboratory  assessment s) 
at Day 29  
Phase 3  
Primary:  
• Proportion of subjects recovered (defined as  alive, free of 
respi[INVESTIGATOR_1399]  [e.g., need for non -invasive or invasive 
mechanical ventilation, high flow oxygen, or ECMO] , and free of 
renal replacement therapy [RRT]) at Day 29  
Secondary  (assessed at Day 29  unless stated otherwise ): 
 
• Number of renal replacement therapy (RRT) -free days  
• Number of m echanical ventilation -free days   
• All-cause mortality  
• Proportion of subjects experiencing a deterioration from 
baseline (as defined by a 1 -point worsening) to end of treatment 
or Day 29 (whichever comes first) in clinical status using an 11 -
category ordinal scale:  
o 0 – Uninfected; no viral RNA detected  
o 1 – Asymptomatic; viral RNA detected  
o 2 – Symptomatic; Independent  
o 3 – Symptomatic; assistance needed  
o 4 – Hospi[INVESTIGATOR_057]; no oxygen therapy  
o 5 – Hospi[INVESTIGATOR_057]; oxygen by [CONTACT_88543]  
o 6 – Hospi[INVESTIGATOR_057]; oxygen by [CONTACT_342624]  
o 7 – Intubation & Mechanical ventilation; pO2/FIO2 >/= 
150 or SpO2/FIO2 >/=200  
o 8 – Mechanical ventilation SpO2/FIO2 < 150  
(SpO2/FIO2 <200) or vasopressors  
o 9 – Mechanical ventilation pO2/FIO2 < 150 and 
vasopressors, dialysis or ECMO  
o 10 – Death  
Exploratory  (assessed at Day 2 9 unless stated otherwise) : 
• Change from baseline in eGFR  
• Time to recovery  
• Recovery at Day 60  
• Change from baseline in PaO 2/ FiO 2 (while hospi[INVESTIGATOR_119813] 
5, 8, 15, and end of treatment)  
Study number:  S20-[ZIP_CODE]   Page 4 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  • Change from baseline in D -dimer, CRP, LDH, troponin and 
cytokine levels ( while hospi[INVESTIGATOR_119813] 5, 8, 15, and end of 
treatment)  
Study Duration  Approximately 12 months  
Participant 
Duration  Approximately 2 months  (including follow -up) 
Duration of IP 
administration  Bardoxolone methyl or placebo will be administered for the duration of 
hospi[INVESTIGATOR_059] (until recovery), with an expected duration of 10 days. 
For patients who are still hospi[INVESTIGATOR_117329] 10 days, treatment 
can be continued for a maximum treatment duration of 29 days.  
Study number:  S20-[ZIP_CODE]   Page 5 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Population  Diagnosis and main criteria for inclusion:  
1. Laboratory -confirmed COVID -19 infection as determined by 
[CONTACT_940] (PCR)  
2. Hospi[INVESTIGATOR_342593]:   
(i) Radiographic infiltrates by [CONTACT_9661] (chest x -ray, CT scan, 
etc.); OR  
(ii) At rest, blood oxygen saturation ≤ 94%; OR   
(iii) Require supplemental oxygen; OR  
(iv) Requiring non -invasive ventilation; OR  
(v) Requiring invasive mechanical ventilation for up to 2 days.  
3.  Age ≥ 18 years.  Enrollment of patients ≥70 years of age may 
be limited (e.g., comprise no more than 10% of all randomized 
patients), pending safety review by [CONTACT_342625]  
4. Participant or legally authorized representative is willing to give 
informed consent  
Exclusion criteria:  
1. Intubated and on invasive mechanical ventilation for three or 
more days at the time of randomization   
2. Known left ventricular ejection fraction (LVEF)  <40% or prior 
hospi[INVESTIGATOR_19934]  
3. Cardiac arrest   
4. Shock  
5. Known u ncontrolled bacterial, fungal, or non -COVID viral 
infection  
6. eGFR < 30 ml/min/1.[ADDRESS_424337] > 5X ULN  
8. History of cirrhosis, chronic active hepatitis or severe hepatic 
disease  
9. Pregnant or lactating women  
10. Enrolled in other trial of unapproved therapi[INVESTIGATOR_014] , unless approved 
by [CONTACT_342626] . In general, co -enrollment will be 
permitted unless ther e are safety concerns, mechanistic 
incompatibility or inability to adjudicate serious adverse events  
and will be decided on a case by [CONTACT_413] .  
11. If in the opi[INVESTIGATOR_111047], progression to death is 
imminent and inevitable within the next 24 ho urs, irrespective of 
the provision of treatments   
Study Sites  Approximately 20 sites 
Number of 
participants  Approximately 400 -440 participants across approximately 20 sites 
Description of 
Study 
Agent/Procedure  Bardoxolone methyl will be administered orally at 20 mg once daily. 
Patients unable to receive oral dosing will receive study drug via a 
nasogastric or orogastric tube.  
Study number:  S20-[ZIP_CODE]   Page 6 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Reference Therapy  Placebo  
Statistical Analysis  A total sample size of approximately 400 participants (Phase 2 
combined with Phase 3 , or Phase 3 alone ) randomized 1:1  using 
permuted block  randomization  (~200 bardoxolone methyl; ~200 
placebo) is expected to provide approximately 80% power at a two -
sided 0.[ADDRESS_424338] a  risk difference of +14% , assuming the following:  
• Follow -up for events for 28 days after randomization 
(through Day 29)  
• 2% of patients in each group drop -out prior to recovery  
• Recovery for 50% patients randomized to placebo relative to 
64% of patients randomized to bardoxolone methyl.  
At a designated time during the trial ( ~40% and ~70% of projected 
sample size has  accrued) interim analysis will be performed for safety, 
harm, and futility.  
The analysis will be based on intention to treat  using a generalized 
linear model analysis  to compare the probability of recovery at Day 
29.  The phase [ADDRESS_424339] the overall type I error rate of the trial. If the DSMB 
concludes the trial should continue to the Phase 3 part, then the phase 
2 patients will be included in the phase 3 portion of the study  (unless 
Phase 2 is unblinded as discussed in Section  8.6).  
 
  
Study number:  S20-[ZIP_CODE]   Page 7 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Schematic of Study Design  for Phase II and Phase III  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Study number:  S20-[ZIP_CODE]   Page 8 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_424340], SKI 9R -109 
[LOCATION_001], NY [ZIP_CODE]  
 
[EMAIL_6642]  
Sub-Investigator  Atul Sharma, MD  
 NYU Langone Hospi[INVESTIGATOR_307] -Brooklyn  
[ADDRESS_424341],  
Brooklyn, NY [ZIP_CODE]  
 
[EMAIL_6643]  
Sub-Investigator  Alexander Slotwiner, MD  NYU Langone Hospi[INVESTIGATOR_307] -Brooklyn  
[ADDRESS_424342],  
Brooklyn, NY [ZIP_CODE]  
 
[EMAIL_6644]  
Sub-Investigator  Juan Gaztanaga, MD  
 [LOCATION_001] University Winthrop  
[ADDRESS_424343]  
Mineola, NY [ZIP_CODE]  
 
[EMAIL_6645]  
Sub-Investigator  Kevin Marzo , MD 
 [LOCATION_001] University Winthrop  
[ADDRESS_424344]  
Mineola, NY [ZIP_CODE]  
 
Kevin.Marzo @nyulangone.org  
Sub-Investigator  Eugene Yuriditsky, MD  
 [LOCATION_001] University Langone Health,  
[ADDRESS_424345]  
[LOCATION_001], NY [ZIP_CODE]  
 
[EMAIL_6646]  
Sub-Investigator  James Horowitz, MD  [LOCATION_001] University Langone Health,  
[ADDRESS_424346]  
[LOCATION_001], NY [ZIP_CODE]  
 
[EMAIL_6647]  
Sub-Investigator  Norma Keller , MD  [LOCATION_001] University Langone Health,  
[ADDRESS_424347]  
[LOCATION_001], NY [ZIP_CODE]  
 
[EMAIL_6648]  
Study number:  S20-[ZIP_CODE]   Page 9 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_424348]  
[LOCATION_001], NY [ZIP_CODE]  
 
[EMAIL_6649]  
Clinical Coordinating 
Center  NYU Clinical Coordinating 
Center  Translational Research Building  
[ADDRESS_424349], 8th Floor  
[LOCATION_001], NY [ZIP_CODE]  
 
[EMAIL_6650]  
Data Coordinating 
Center  NYU Clinical Research 
DataCore  [ADDRESS_424350] South  
[LOCATION_001], NY [ZIP_CODE]  
 
[EMAIL_6650]   
Statistician  Charles Cleland, PhD  [ADDRESS_424351], 2 -53 
[LOCATION_001], NY [ZIP_CODE]  
  
[EMAIL_6651]  
Reata Medical Contact  [CONTACT_342627], Inc.  
[ADDRESS_424352], Plano, TX  
 
Phone: 469 -262-6622  
Email: [EMAIL_6652]  
Sub-Investigator  Sudhakar Prabhu , MD  NYC Health + Hospi[INVESTIGATOR_600]/Coney Island  
[ADDRESS_424353]  
Brooklyn, [LOCATION_001] [ZIP_CODE]  
 
Email: [EMAIL_6653]  
Sub-Investigator  Mazullah Kamran , MD  NYC Health + Hospi[INVESTIGATOR_600]/Elmh urst 
79-[ADDRESS_424354], [LOCATION_001] [ZIP_CODE]  
 
Email: [EMAIL_6654]  
 
2 Introduction , Background Information and Scientific Rationale  
2.1 Background Informatio n and Relevant Literature  
Infection with the recently identified SARS -CoV-2 virus leads to an illness known as COVID -19. Mild cases 
of COVID -19 generally resolve quickly; however, some patients with moderate -to-severe COVID -19 rapi[INVESTIGATOR_342594] (ARDS), 
Study number:  S20-[ZIP_CODE]   Page 10 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  acute kidne y injury (AKI), and multiple organ failure ( Sarzi -Puttini, 2020; Huang, 2020; Chen, 2020; 
Guan,2020 ). The severity of COVID -19, as well as the development of serious complications, is associated 
with an imbalance in the response of the immune system to the infection with excessive production of pro -
inflammatory cytokines and chemokines  (Liu, 2020 ). The Keap1 -Nrf2 system rapi[INVESTIGATOR_342595], 
including detoxification, antioxidant, and anti -inflammatory networks ( Dinkova -Kostova, 2015 ).  
The potent anti -inflammatory effects of bardoxolone methyl in cultured cells has translated into broad 
protective activity in animal models of acute lung injury and inflammation ( Nichols, 2009, Chen 2015, Pei, 
2019; Reddy, 2009; Zhang, 2019; Nagashima, 2019; Kulkarni, 2013 ). Bardoxolone methyl and analogs 
significantly reduce neutrophil and macrophage infiltration and suppress proinflammatory cytokine and 
chemokine le vels in the lungs of mice treated with inflammatory stimuli ( Nichols, 2009; Chen 2015, Reddy, 
2009 ). In these models, bardoxolone methyl and analogs also reduced pulmonary edema, decreased lung 
injury scores, prevented fibrosis, and improved lung function (Chen 2015; Pei, 2019; Kulkarni, 2013 ).  
Bardoxolone methyl and analogues also reduce proinflammatory cytokines and chemokines, prevent organ 
damage (lung, liver, and pancreas), and increase survival in models of systemic inflammation 
(Thimmulappa, 2006; A uletta, 2010, Osburn, 2008; Keleku -Lukwete, 2015; Robles, 2016 ).  
In addition to their anti -inflammatory and tissue protective activity, bardoxolone methyl and analogs have 
been shown to inhibit viral replication, suppress viral infection, inhibit transcri ption of viral genes, and 
prevent latent viral reactivation in vitro  (Vázquez, 2005; Shao, 2016; Chandra, 2018; Patra, 2019; Nio, 2019; 
Wyler, 2019; Rothan, 2019 ). Consistent with the mechanism of action of these compounds, the Nrf2 target 
heme oxygenase -1 (HO-1) has been shown to exhibit significant antiviral activity ( Espi[INVESTIGATOR_103881], 2017 ). 
In patients with COVID -19, AKI has been reported to occur in up to 28% of all patients and up to 72% of 
non-survivors ( Fanelli, 2020; Yang, 2020; Zhou, 2020; Naicker, 2020 ). Bardoxolone methyl and analogues 
protect kidney tissue, reduce inflammation, prevent fibrosis, and increase kidney function in animal models 
of chronic kidney disease and AKI ( Chin, 2013; Tanaka, 2008; Wu, 2011; Aminzadeh, 2013 ).  Moreover, 
bardoxolone me thyl has been shown to improve kidney function —assessed using a variety of measures 
including measured inulin clearance, creatinine clearance, and estimated glomerular filtration rate —in 
patients with diabetes, Alport syndrome, autosomal dominant polycysti c kidney disease (ADPKD), IgA 
nephropathy (IgAN), and focal segmental glomerular sclerosis (FSGS) ( Pergola, 2011; de Zeeuw, 2013 ). 
The profile of eGFR increases with bardoxolone methyl reflects its multiple protective and anti -inflammatory 
effects.  Early improvements in eGFR evident within the first 4 weeks of bardoxolone methyl treatment are 
likely attributed to the reversal of acute, dynamic inflammation -mediated processes such as endothelial 
dysfunction and mesangial cell contraction resulting in glomer ular filtration surface area increases 
(Aminzadeh, 2013; Chin, 2018; Ding, 2013; Ferguson, 2010 ).   
Taken together, the broad anti -inflammatory, antiviral, and tissue protective activities of bardoxolone methyl 
suggest that it may reduce the excessive production of cytokines and chemokines and prevent ARDS and 
AKI in patients with COVID -19. 
2.2 Name [CONTACT_342680], an investigational drug, has been shown to activate the Keap1 -Nrf2 system, which 
allows Nrf2 to increase expression of antioxidant and cytoprotective genes and decrease expression of pro -
inflammatory NF -κB target genes ( Lee, 2009; Dinkova -Kostova, 2005; Rojas -Rivera, 2012; Osburn & 
Kensler, 2008 ).  Consistent with this activity, bardoxolo ne methyl and analogues suppress proinflammatory 
cytokines and chemokines and reduce oxidative stress in many cell types in response to a variety of 
inflammatory triggers ( Chen 2015; Thimmulappa, 2007; Pei, 2019, Nichols, 2009 ).  Approximately [ADDRESS_424355] been exposed to bardoxolone methyl in clinical trials , including studies in patients with 
cancer, chronic kidney disease (CKD), and pulmonary hypertension (PH) .  
2.2.[ADDRESS_424356] 
protective activity in animal models of acute lung injury and inflammation ( Nichols, 2009, Chen 2015, Pei, 
2019; Reddy, 2009; Zhang, 2019; Nagashima, 2019; Kulkarni, 2013 ). Bardoxolone methyl and analogs 
Study number:  S20-[ZIP_CODE]   Page 11 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  significantly re duce neutrophil and macrophage infiltration and suppress proinflammatory cytokine and 
chemokine levels in the lungs of mice treated with inflammatory stimuli ( Nichols, 2009; Chen 2015, Reddy, 
2009 ). In these models, bardoxolone methyl and analogs also redu ced pulmonary edema, decreased lung 
injury scores, prevented fibrosis, and improved lung function ( Chen 2015; Pei, 2019; Kulkarni, 2013 ).  
Bardoxolone methyl and analogues also reduce proinflammatory cytokines and chemokines, prevent organ 
damage (lung, li ver, and pancreas), and increase survival in models of systemic inflammation 
(Thimmulappa, 2006; Auletta, 2010, Osburn, 2008; Keleku -Lukwete, 2015; Robles, 2016 ).  
In addition to their anti -inflammatory and tissue protective activity, bardoxolone methyl an d analogs have 
been shown to inhibit viral replication, suppress viral infection, inhibit transcription of viral genes, and 
prevent latent viral reactivation in vitro  (Vázquez, 2005; Shao, 2016; Chandra, 2018; Patra, 2019; Nio, 2019; 
Wyler, 2019; Rothan, 2 019). Consistent with the mechanism of action of these compounds, the Nrf2 target 
heme oxygenase -1 (HO -1) has been shown to exhibit significant antiviral activity ( Espi[INVESTIGATOR_103881], 2017 ). 
Lastly, preclinical studies have demonstrated that bardoxolone methyl and analogues protect kidney tissue, 
reduce inflammation, prevent fibrosis, and increase kidney function in many different animal models of 
kidney disease, including:  ischemia -reperfusion -induced acute kidney injury (AKI) ( Liu, 2014 ), chemically 
induced ac ute kidney injury (AKI) ( Tanaka, 2008 ; Aleksunes, 2010 ; Wu, 2014 ), CKD associated with 
diabetes and/or obesity ( Chin, 2013 ; Tan, 2014 ; Camer, 2016 ), CKD caused by [CONTACT_342628] ( Aminzadeh, 
2013 ; Aminzadeh, 2014 ; Son, 2015 ), CKD caused by [CONTACT_342629] (Nagasu, 2019 ), autoimmune -
associated kidney disease ( Wu, 2014 ), and h ypertension -associated kidney disease ( Hisamichi, 2018 ). 
2.2.[ADDRESS_424357] been exposed to bardoxolone methyl in clinical trials, including studie s 
in healthy subjects, patients with cancer, pulmonary hypertension (PH), and various forms of chronic kidney 
disease (CKD). As described in Section Error! Reference source not found. , bardoxolone methyl has 
been shown to improve kidney function —assessed using a variety of measures including measured inulin 
clearance, creatinine clearance, and estimated glomerular filtration rate —in patients with CKD due to 
diabetes, Alport syndrome, autosomal dominant polycystic kidney disease (ADPKD), IgA nephropathy 
(IgAN), and focal segmental glomerular sclerosis (FSGS) ( Pergola, 2011; de Zeeuw, 2013 ). 
The profile of eGFR increases with bardoxolone methyl reflects its multiple protective and anti -inflammatory 
effects.  Early improvements in eGFR evident within the first 4 weeks of bardoxolone methyl treatment are 
likely attributed to the reversal of acute, dynamic inflammation -mediated processes such as endothelial 
dysfunction and mesangia l cell contraction resulting in glomerular filtration surface area increases 
(Aminzadeh, 2013; Chin, 2018; Ding, 2013; Ferguson, 2010 ).   
Please refer to the Investigator’s Brochure for a detailed discussion of safety findings for studies in healthy 
subjec ts, cancer, CKD, and PH patients with bardoxolone methyl.  
2.2.3 Dose Rationale (if applicable)  
Several dose -ranging studies which have been conducted with bardoxolone methyl demonstrated that 
changes in eGFR are dose -dependent.  The [ADDRESS_424358] of the available clinical safety and efficacy data for bardoxolone methyl has 
been collected wit h the 20 mg dose.   
2.3 Rationale  
Some patients with moderate -to-severe COVID -19 rapi[INVESTIGATOR_342596], AKI, and multiple organ failure. The severity of COVID -19, as well as the 
development of serious complica tions, is associated with an imbalance in the response of the immune 
system to the infection with excessive production of pro -inflammatory cytokines and chemokines.  
Bardoxolone methyl and analogues exhibit potent anti -inflammatory activity in vitro. Moreov er, bardoxolone 
and analogues suppress inflammation and tissue damage in animal models of acute lung injury and reduce 
mortality in models of systemic inflammation. In addition to the anti -inflammatory and tissue protective 
Study number:  S20-[ZIP_CODE]   Page 12 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_424359] 
bardoxolone methyl may reduce the excessive production of cytokines and chemokines and prevent ARDS 
and AKI in patients with COVID -19. 
2.4 Potential  Risks & Benefits  
2.4.1 Known Potential Risks  
Please refer to the Investigator’s Brochure for a detailed discussion of safety findings for studies conducted 
with bardoxolone methyl in healthy subjects  or patients with cancer, CKD, or PH. 
[IP_ADDRESS] Fluid Overload  
Similar to endothelin receptor antagonists (ERAs) in certain patient populations, including bosentan in 
advanced congestive heart failure and avosentan in advanced CKD, bardoxolone methyl treatment was 
found to be associated with an increased risk  for fluid overload and heart failure hospi[INVESTIGATOR_342597], which enrolled patients with Stage 4 CKD (eGFR  15 to 29 mL/min/1.73 m2) and type 2 
diabetes ( Chin, 2014 ).  The overall increased risk for fluid overload and heart failure events wi th 
bardoxolone methyl appeared to be limited to the first three to four weeks after initiation of treatment.  
Patients with fluid overload events who were treated with intravenous diuretics generally resolved their 
symptoms.  Elevated BNP and prior hospi[INVESTIGATOR_342598].  For patients without these baseline characteristics, the risk 
for heart failure events among bardoxolone methyl - and placebo - treated patients was similar (2%)  (Chin, 
2014 ).  The increased risk for these events from bardoxolone methyl treatment had also not been observed 
in six previous CKD studies, which were conducted mostly in patients with Stage 3b CKD (eGFR of 30 to 
44 mL/min/1.73  m2), patie nts with hepatic dysfunction or cancer, or healthy volunteers.  
Subsequent studies, enrolling over [ADDRESS_424360] been applied, no increased risk for acute fluid overload AEs with bardoxolone 
methyl has been observed .  As such, BARCONA will exclude patients with known left ventricular ejection 
fraction (LVEF) <40% or prior hospi[INVESTIGATOR_342599].  
[IP_ADDRESS] Transaminase and Gamma -glutamyl Transpeptidase (GGT) Elevations  
In clinical studies of ba rdoxolone methyl, almost all patients had increases of transaminase enzymes above 
baseline upon initiation of treatment, which followed a consistent pattern.  These increases were not 
associated with elevations in bilirubin or other signs of liver toxicity .  In BEACON, fewer hepatobiliary SAEs 
were observed in the bardoxolone methyl arm than in the placebo arm.  The elevations begin immediately 
after initiation of treatment or an increase in dose; they peak approximately two to four weeks later.  In most 
patients, transaminase elevations were mild, but approximately 4% to 11% of patients experienced an 
elevation greater than 3X the ULN.  The elevations resolved to levels less than the ULN in most all patients 
with elevations, within two weeks after peak valu es while patients continued taking study drug.  Patients 
who experienced elevations to greater than 3X the ULN sometimes required additional time to resolve.  
While some patients have had elevations to above 3X the ULN, persistent elevations to above 3X th e ULN 
have not been observed, and the elevations did not recur once resolved, unless caused by [CONTACT_1604].  
Bardoxolone methyl regulates GGT, a known Nrf2 target gene.  In clinical studies, low level GGT elevations 
during treatment were common, mild, and  typi[INVESTIGATOR_342600]/AST elevations.  Bilirubin levels 
in patients experiencing transaminase or GGT elevations due to treatment with bardoxolone methyl either 
remained at baseline levels or decreased.  The ALT, AST, and GGT elevations were gen erally self -limiting 
in patients who continued treatment with study drug.  
Study number:  S20-[ZIP_CODE]   Page 13 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  [IP_ADDRESS] Muscle Spasms  
Muscle spasm was the most frequently reported adverse event in clinical trials of bardoxolone methyl in 
patients with CKD who also had type [ADDRESS_424361] not been consistent with muscle 
toxicity.  Bardoxolone methyl subjects showed no increase in prominent laboratory findings associated with 
musc le toxicity, such as increased levels of serum markers, including creatinine, creatine kinase, lactate 
dehydrogenase (LDH), BUN, uric acid, phosphorus, and potassium.  
2.4.[ADDRESS_424362] been observed with bardoxolone methyl treatment in multiple clinical studies, including 
patients with CKD, cancer, and pulmonary hypertension (PH).  Bardoxolone methyl was originally 
consider ed for development in cancer patients, and in two Phase 1 studies, bardoxolone methyl was 
observed to reduce serum creatinine levels, corresponding to an increase in eGFR ( Hong, 2012 ).  The 
reductions of serum creatinine concentrations and resultant increa ses in eGFR were time -dependent and 
manifested in a majority (82%) of the patients studied.  In subsequent studies that enrolled over [ADDRESS_424363] one year in treated 
patients ( Chin, 2018; Pergola, 2011 ).  The change in serum creatinine was not related to a reduction in 
creatinine generation ( Chertow, 2018 ); improved kidney funct ion was confirmed in a study of Japanese 
patients with type 2 diabetes wherein GFR was measured using inulin clearance, as well as estimated, 
using conventional GFR estimating equations ( Nangaku, 2020 ). 
Most recently, bardoxolone methyl was shown to signif icantly increase eGFR in patients with CKD due to 
Alport syndrome, ADPKD, IgAN, T1D CKD, or FSGS ( Pergola, 2019 ). The clinical activity of bardoxolone 
methyl in various forms of CKD with distinct etiologies suggests that the anti -inflammatory and anti -fibrotic 
effects of bardoxolone methyl target the common final pathway contributing to GFR loss in multiple forms 
of CKDs.  
Table 1: Cross-Study Comparison of Increases in eGFR, Inulin Clearance, and 
Creatinine Clearance with Bardoxolone Methyl Treatment  
Study Phase/ 
Country Study 
Population  # of 
Patients Treatment 
Duration  ∆eGFR 
(mL/min/1.73m2)(1) 
CKD Studies  
402-C-0801  
(Stratum 1)  
(open label)  2a/ 
US Age ≥ 18,  
Diabetic nephropathy  60 28 days 6.7 
(p<0.001)  
402-C-0801  
(Stratum 2)  
(open label)  2b/ 
US Age ≥ 18,  
Diabetic nephropathy  20 56 days 7.2 
(p<0.001)  
CrCl also sig. 
increased  
402-C-0804 
(BEAM) 2/ 
US Age ≥ 18,  
T2D and CKD  227 52 weeks  8.6 at WK52  
(p<0.001 vs PBO)  
402-C-0902 2/ 
US Age ≥ 18, T2D and CKD  131 85 days 6.5 
(p<0.001)  
402-C-0903 
(BEACON)  3/ 
Global Age ≥ 18,  
T2D and Stage 4 CKD  2185 Median: 
7 months with 522 
patients through 
Week 48 6.4 
(p<0.001 vs PBO)  
CrCl also significantly 
increased  
Study number:  S20-[ZIP_CODE]   Page 14 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  402-C-1102 1/US Age ≥ 18,  
T2D and Stage 3b and Stage 
4 CKD 24 56 days 9.0 
(p<0.05) 
RTA402-005 
(TSUBAKI)  2/ 
Japan Age ≥ 20,  
T2D and Stage 3 and 4 CKD  108 16 weeks  6.6 (inulin GFR)  
(p=0.008 vs PBO)  
402-C-1603 2/US Age 12 to 65,  
Alport Syndrome  30 48 weeks  10.4 (p<0.001)  
402-C-1603 3/Global Age 12 to 70,  
Alport Syndrome  157 48 weeks  9.5  
(p<0.001 vs PBO)  
402-C-1702 2/US Age 18 to 70,  
ADPKD 31 12 weeks  9.3 (p<0.001)  
402-C-1702 2/US Age 18 to 70,  
IgA Nephropathy   26 12 weeks  8.0 (p<0.001)  
402-C-1702 2/US Age 18 to 70,  
T1D CKD  28 12 weeks  5.5 (p=0.02) 
Non-CKD Studies  
402-C-0501 1/ 
US Age ≥ 18,  
Advanced Solid Tumors or 
Lymphoid Malignancies  47 Median:  
56 days 18.2 
(p<0.0001)  
402-C-0702 1/2/ 
US Pancreatic Cancer  34 Median:  
56 days 32.2 
(p=0.001)  
402-C-1302 
(LARIAT)  2/ 
US Age 18 to 75  
PH (Baseline eGFR  
82 mL/min/1.73 m2) 54(2) 16 weeks  14.7 
(p<0.001 vs PBO)  
a Unless noted, data are mean eGFR changes from baseline for bardoxolone methyl patients and p-values are 
calculated from two -sided paired t -tests comparing eGFR change to 0.  
b Number of patients enrolled in Cohorts 1 an d 2. 
 
 
3 Objectives and Purpose  
3.1 Phase 2  
3.1.1 Primary Objective  
• To provide an initial  assess ment of  the safety of bardoxolone methyl in COVID -19 patients when 
compared with matching placebo  
3.2 Phase 3  
3.2.1 Primary Objective s 
• To determine whether bardoxolone methyl in COVID -19 patients increases the probability of 
recovery at Day 29  when compared with matching placebo  
• To assess the safety of bardoxolone methyl in COVID -19 patients when compared with matching 
placebo 
3.2.2 Secondary and Exploratory Objectives  
• To assess the effect of bardoxolone methyl on other endpoints including renal function when 
compared with matching placebo  
3.2.3. Safety Endpoints  
The following safety endpoints will be assessed during the study:  
Study number:  S20-[ZIP_CODE]   Page 15 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  • All adverse events that are serious , unexpected,  and have a reasonable possibility of having been 
related to the study drug  
• All unexpected deaths  
4 Study Design  and Endpoints  
4.1 Description of Study Design  
This multi -center, double -blind, placebo -controlled, rando mized Phase 2/3 trial will study the safety, 
tolerability, and efficacy of bardoxolone methyl in patients hospi[INVESTIGATOR_249096] -19.  Phase 2  
is designed to provide an early interim analysis  for safety  and will enroll  approximately 40 patients . Phase 
3 is designed to determine whether bardoxolone methyl increases  the probability of recovery  at Day 29 
compared with mat ching placebo. In phase 3, approximately 360-400 additional patients will be enrolled.  
 
Patients will be randomized using permute d block  randomization in a 1:1 fashion to either once -daily 
administration of bardoxolone methyl (20 mg) or matching placebo.  Randomization  will be stratified by 
[CONTACT_342622] (i.e., mechanical ventilation with endotrach eal intubation) 
use at baseline (yes or no).   
 
Enrollment of patients ≥70 years of age may be limited (e.g., comprise no more than 10% of all randomized 
patients) , pending safety review by [CONTACT_342623] .  Treatment will be administered 
for the duration of hospi[INVESTIGATOR_059] (until recovery), with an expected duration of 10 days. For patients who 
are still hospi[INVESTIGATOR_117329] 10 days, treatment can be continued for a maximum treatment duration 
of 29 d ays. Dose de -escalation (down to 10  mg) is permitted during the study if indicated clinically, and 
subsequent dose  re-escalation is also permitted.  Once a patient’s dose has been reduced, dose re -
escalation back to a higher dose is permitted.  
 
Randomizati on will be performed using an interactive web response system (IWRS).   Following 
randomization on Day 1, patients will be assessed while  hospi[INVESTIGATOR_342601] 3, 5, 8, 11, 15, 22, and 29.  
Assessments will include clinical status assessments, vital sign me asurements, clinical chemistry 
collection, and adverse event collection.  Patients that recover prior to Day [ADDRESS_424364]’s ability 
to return to the site for the visit. In this case, the visit may be performed by [CONTACT_648].   An independent Data 
and Safety Monitoring Board (DSMB)  will advise the study leadership on safety aspects and over all 
progress of the study.  
 
The phase 2 primary endpoint will be assessed during the treatment phase, defined as while hospi[INVESTIGATOR_342602] 15 . The phase 3 primary endpoint will be assessed during the treatment phase, defined as 
while hospi[INVESTIGATOR_342603] 29.  Enrollment of the phase 3 cohort  will initiate after safety and proof of 
concept has been confirmed in the Phase 2 cohort.   
4.2 Study Endpoints  
4.2.1 Phase 2  
[IP_ADDRESS] Primary Endpoint  
• Safety (e.g., frequency, intensity, and relationship to stud y drug of serious adverse events 
[including unexpected deaths], change from baseline in vital sign and laboratory assessments)  at 
Day 29  
Study number:  S20-[ZIP_CODE]   Page 16 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  4.2.2 Phase 3  
[IP_ADDRESS] Primary Efficacy Endpoint  
• Proportion of subjects recovered (defined as alive, free of respi[INVESTIGATOR_1399] [e.g. , need for non -
invasive or invasive mechanical ventilation, high flow oxygen, or ECMO], and free of renal 
replacement therapy [RRT]) at Day 29 .  
[IP_ADDRESS] Seconday Efficacy Endpoint  (assessed at Day 29  unless stated otherwise ) 
• Number of renal replacement therapy (RR T)-free days  
• Number of mechanical ventilation -free days   
• All-cause mortality  
• Proportion of subjects experienc ing a deterioration from baseline (as defined by a 1 -point 
worsening) to end of treatment or Day 29 (whichever comes first) in clinical status using an 11 -
category ordinal scale:  
o 0 – Uninfected; no viral RNA detected  
o 1 – Asymptomatic; viral RNA detected  
o 2 – Symptomatic; Independent  
o 3 – Symptomatic; assistance needed  
o 4 – Hospi[INVESTIGATOR_057]; no oxygen therapy  
o 5 – Hospi[INVESTIGATOR_057]; oxygen by [CONTACT_88543]  
o 6 – Hospi[INVESTIGATOR_057]; oxygen by [CONTACT_342624]  
o 7 – Intubation & Mechanical ventilation; pO2/FIO2 >/= 150 or SpO2/FIO2 >/=200  
o 8 – Mechanical ventilation pO2/FIO2 < 150  (SpO2/FIO 2 <200) or vasopressors  
o 9 – Mechanical ventilation pO2/FIO2 < 150 and vasopressors, dialysis or ECMO  
o 10 – Death  
[IP_ADDRESS] Exploratory Efficacy Endpoint  (assessed at Day 29 unless stated otherwise)  
• Change from baseline in eGFR  
• Time to recovery  
• Recovery at Day 60   
• Change from baseline in PaO2/ FiO2 ( while hospi[INVESTIGATOR_119813] 5, 8, 15, and end of treatment)  
• Change from baseline in D -dimer, C -reactive protein (CRP), LDH, troponin and cytokine levels 
(while hospi[INVESTIGATOR_119813] 5, 8, 15, and end of treatment)  
[ADDRESS_424365] meet all of the following criteria:  
1. Laboratory -confirmed COVID -19 infection as determined by [CONTACT_940] (PCR)  
2. Hospi[INVESTIGATOR_342604]:   
a. Radiographic infiltrates by [CONTACT_9661] (chest x -ray, CT scan, etc.); OR  
Study number:  S20-[ZIP_CODE]   Page 17 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_424366], blood oxygen saturation ≤ 94%; OR   
c. Require supplemental oxygen; OR  
d. Requiring non -invasive ventilation; OR  
e. Requiring invasive mechanical ventilation for up to 2 days.  
3.  Age ≥  18 years.  Enrollment of patients ≥70 years of age may be limited (e.g., comprise no more 
than 10% of all randomized patients) , pending safety review by [CONTACT_342623]  
4. Participant or legally authorized representative is willing to give informed consent  
5.2 Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation in this study:  
1. Intubated and  on invasive mechanical ventilation for three or more days at the time of 
randomization   
2. Known left ventricular ejection fraction (LVEF) <40% or prior hospi[INVESTIGATOR_19934]  
3. Cardiac arrest   
4. Shock  
5. Known u ncontrolled bacterial, fungal, or non -COVID viral infection  
6. eGFR < 30 ml/min/1.[ADDRESS_424367] > 5X ULN  
8. History of cirrhosis, chronic active hepatitis or severe hepatic disease  
9. Pregnant or lactating women  
10. Enrolled in other trial of unapproved therapi[INVESTIGATOR_014], unless approv ed by [CONTACT_342626]. In 
general, co -enrollment will be permitted unless there are safety concerns, mechanistic 
incompatibility or inability to adjudicate serious adverse events  and will be decided on a case by 
[CONTACT_413] .  
11. If in the opi[INVESTIGATOR_111047], progression to death is imminent and inevitable within the next 
24 hours, irrespective of the provision of treatments   
5.3 Vulnerable Subjects  
The study will include subjects with diminished or lack of capacity to provide consent if their Legally 
Authorized Representative (LAR)  is able to provide consent on their behalf. Due to the known progression 
of the COVID -[ADDRESS_424368]’s capacity will be conducted by [CONTACT_342630] , which includes asses sment of patients understanding of the facts 
presented, assessment of their appreciation and reasoning about the choice , etc. and communicated to the 
study team. If it is determined that  the subject is unable to provide consent, consent will be obtained fr om 
subject’s LAR before study -related procedures can begin. The study will be explained to the LAR by [CONTACT_342631] -approved Informed Consent Form. The hierarchy of identifying the LAR will be in 
the following order: health care agent , spous e (if not legally separated), domestic partner, adult child, 
parent, adult sibling, and close friend. The hierarchy may vary from state to state and the local site should 
refer to their local regulatrions. Identification and verification of the LAR will fo llow the standard policies and 
procedures in place at each study site.  
 
Study number:  S20-[ZIP_CODE]   Page 18 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Subjects’ capacity will be re-assessed at each study visit  with the treatment team. Once the participant 
regains capacity to consent, they will be informed of their participation in th e study and will have an 
opportunity to withdraw from further participation in the study.  Subjects who  regain the capacity to consent 
and decline to co ntinue participation  will be asked if previously collected data can still be used. If they 
decline  to all ow use of previously collected data, their  data will be discarded.  If a subject provides consent 
with capacity, and subsequently loses capacity, their participation in the study is expected to  continue 
unless  the LAR notifies the study team of study withdr awal.  
5.[ADDRESS_424369] the participant’s treating physician  (TP), or equivalent, 
to further verify eligibility for the study. The Investigator and TP will determine the best way to approach the 
potential participant to introduce the study. The consenting process will occur in an in -patient setting.  In 
addition to screening by [CONTACT_3476], the Principal Investigator [INVESTIGATOR_342605]. Referrals from clinical colleagues will be reviewed 
to verify eligibility before proceeding to the consenting process.  
5.5 Duration of Study Participation 
Bardoxolone methyl or placebo will be administered for the duration of hospi[INVESTIGATOR_3094] (until recovery) , for 
up to a maximum of 29 days . A final follow -up visit  will occur  60 days after randomization . Total duration of 
study participation is estimated to be approximately 2 months.   
5.6 Total Number of Participants  and Sites  
Recruitment will  end when approximately 400-440 participants are enrolled.  Recruitment is planned to 
occur at approximately 20 sites.  
5.7 Participant Treatment Discontinuation  
5.7.1 Reasons for Treatment Discontinuation  
Study drug discontinuation refers to a patient’s stoppi[INVESTIGATOR_342606].  Participants are free 
to discontinue study treatment at any time for any reason without prejudice to their medical care.  
Furthermore, the investigator may disconintue  a patient from study drug.  The reason for a patient’s 
discontinuation from stu drug will be rcorded in the electronic case report form (eCRF).   
Reasons for study drug discontinuation may include the following:  
• Adverse event;  
• Death;  
• Lost to follow -up; 
• Physician decision;  
• Protocol specified criterion met;  
• Withdrawal by [CONTACT_342632], complete all study visits, 
and undergo all scheduled study assessments, if possible.   
5.[ADDRESS_424370] , without prejudice 
to their medical care . The reason for a patient’s withdrawal or  termination will be recorded in an electronic 
case report form (eCRF).  The potential reasons could be:  
Study number:  S20-[ZIP_CODE]   Page 19 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019   
• Withdrawal of Consent by [CONTACT_25302]  
• Lost to Follow -up 
 
Discontinuation of treatment is not a withdrawal of participation from the study. If treatment is discontinued, 
the participant should remain in the study and continue to  be assessed at the scheduled study 
assessments . 
5.8.2 Handling of Participant Withdrawals or Termination  
If a participant (or legally authorized representative who provided consent) noti fies the study team about 
withdrawing participation from the study , the study team will make all efforts to collect data related to the 
primary and secondary endpoints . 
 
The investigator will make reasonable efforts  to obtain, at a minimum, survival data on all participants lost 
to follow -up.  Before a participant is considered lost to follow -up, study team will use any combination of the 
following methods to ascertain vital status:  
• Multiple phone calls to participan t and/or their next -of-kin 
• Send certified letters to known addresses  
• Search medical records system  for recent routine visits  
 
The overall clinical care of this patient will not change as a result of participation in this study nor will it 
change should the  patient be withdrawn for any reason.   
5.9 Premature Termination or Suspension of Study  
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. 
Written notification, documenting the reason for study suspension  or termination, will be provided by [CONTACT_342633] , funding agency, the IND spo nsor and 
regulatory authorities . If the study is prematurely terminated or suspended, the PI [INVESTIGATOR_342607](s) for the termination or suspension.  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination of futility  
 
Study may resume once concerns about safety, protocol compliance, data quality are addressed and satisfy 
the sponsor, IRB and/or FDA.  
 
Although Reata intend s to complete the study, Reata reserves the right to discontinue the study at any time 
for clinical or administrative reasons, or if required by [CONTACT_17513].  If Reata discontinues the study, 
all study drug will be discontinued  and the investigator will be responsible for securing any alternative 
therapy to be administered, as appropriate.  
6 Study Agent 
6.1 Study Agent(s) and Control Description  
Bardoxolone methyl (RTA 402) drug product information is shown in  Table 2 .  Information ab out the placebo 
is shown in  Table 3 . 
Table 2: Bardoxolone Methyl Drug Product Information  
Description  Bardoxolone methyl capsule (5  mg, 15  mg) 
Study number:  S20-[ZIP_CODE]   Page 20 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Ingredients  Bardoxolone methyl  
Methacrylic Acid – Ethyl Acrylate Copolymer (1:1), 
Type A  
Silicified Microcrystalline Cellulose  
Hydroxypropyl Methylcellulose  
Lactose Monohydrate  
Sodium Lauryl Sulfate  
Colloidal Silicon Dioxide  
Magnesium Stearate  
Gelatin capsules  
Titanium Dioxide (capsule pi[INVESTIGATOR_2517])  
Route of Administration  Oral 
Table 3: Placebo Information  
Description  Placebo for bardoxolone methyl capsule 
(size #4 and size #1)  
Ingredients  Silicified Microcrystalline Cellulose  
Lactose monohydrate  
Magnesium Stearate  
Gelatin capsules  
Titanium Dioxide (capsule pi[INVESTIGATOR_2517])  
Route of Administration  Oral 
 
6.1.[ADDRESS_424371] s will require client approval pr ior to shipment .    
6.1.2 Formulation, Appearance, Packaging, and Labeling  
The study drug will be supplied in tamper -evident sealed kits containing two high -density polyethylene 
(HDPE) bottles . The 20mg kit contain s two (HDPE) bottles  (1) 30ct 15mg bottle and (1) 30ct 5mg bottle. 
The 20 mg dose is attained by [CONTACT_41680] 1 capsule from each bottle as directed. The 10 mg kit contains two 
(HDPE) bottles ( 2) 30ct 5mg bottle s.  The 10mg dose is attained by [CONTACT_41680] [ADDRESS_424372] not be ingested.  Labeling on each 
bottle will contain at minimum the following information:  
• Protocol: s20 -[ZIP_CODE]  
• Product name [CONTACT_58257]  
• Caution : New Drug – Limited by [CONTACT_342634]  
• Keep out of reach of children  
• Control or lot number  
• Store at 15° – 25°C (59° – 77°F)  
Study number:  S20-[ZIP_CODE]   Page 21 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  • Reata Pharmaceuticals, Inc., Irving, TX  
6.1.[ADDRESS_424373] in a secure location with room temperature conditions of 15° - 
25°C (59° - 77°F).  
6.1.4 Preparation  
Patients will be  administered one capsule from each bottle included in the study drug kit orally once a day 
beginning on Day 1 while the patient remains hospi[INVESTIGATOR_057] . Patients unable to receive oral medications 
(e.g., due to intubation and/or mechanical ventilation) may receive the contents of the capsule through a 
nasogastric or orogastric tube flushed with water.   Each dose of study drug should be administered at 
approximately the same time each  day, preferably in the morning.  
6.1.5 Dosing and Administration  
Please refer to  Section [IP_ADDRESS]  for details on study drug administration, which will be administered at the 
time points listed in Table 1.  Patients mu st be instructed to continue taking study drug once daily while 
hospi[INVESTIGATOR_057] (until recovery) with an expected duration of 10 days. For patients who are still hospi[INVESTIGATOR_222268] 10 days, treatment can be continued for a maximum treatment duration o f 29 days .    
6.1.6 Route of Administration  
Bardoxolone methyl will be administered orally. Patients unable to receive oral dosing will receive study 
drug via a nasogastric or orogastric tube . 
6.1.7 Starting Dose  
Patients will be randomized 1:1 to either 20 mg of bardoxolone methyl or placebo.   
6.1.8 Dose Adjustments/Modifications/Delays  
The investigator may choose to decrease the patient’s dose to a lower dose ( e.g., 20 mg to 10  mg), if 
clinically indicated.  Reasons f or dose de -escalation should be documented.  Once a patient’s dose has 
been reduced, dose re -escalation back to a higher dose is permitted.  
6.1.9 Duration of Therapy  
Patients will receive study drug while hospi[INVESTIGATOR_057] (until recovery) with an expected duration o f [ADDRESS_424374] the site regarding the final disposition of study drug.  
Study number:  S20-[ZIP_CODE]   Page 22 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  7 Study Procedures  and Schedule  
7.1 Study Procedures/Evaluations  
7.1.1 Study Specific Procedures  
[IP_ADDRESS] Informed Consent  
Informed consent (see  Section  Error! Reference source not found. ) must be obtained from the patient or 
the legally authorized representative (for patients who cannot consent, for example, those who are 
intubated) before any study -related procedures are per formed, and again if there is a change in the study 
procedures that would affect the patient’s willingness to participate.  
[IP_ADDRESS] Inclusion/Exclusion  
Inclusion and exclusion criteria must be reviewed as indicated in Table 1.  Patients must meet all of the 
inclusion and none of the exclusion criteria for entry in the study.  Investigators should contact [CONTACT_342635] 1.  
[IP_ADDRESS] Demographics and Baseline Disease Characteristics  
Demographic data including sex, age, race, and ethnicity, will be collected as indicated in  
Table 1.  Baseline disease characteristics will be collected as indicated in Table 1.   
[IP_ADDRESS] Prior and Current Concomitant Medications  
The name, dose, and frequency must be recorded for all medications that the patient is taking.  Trade or 
generic drug names should be used where p ossible.  Concomitant medications w ill be reviewed as 
indicated in Table 1 and all changes will be recorded . 
[IP_ADDRESS] Medical History  
A complete medical history that includes all available medical history must be collected.  Medical history 
will be recorded as indicated in Table 1.   
[IP_ADDRESS] Pregnancy Test  
WOCBP  will complete a pregnancy test as indicated in Table 1, or at any time if pregnancy is suspected .  
Any patient who becomes pregnant during the study mus t discontinue taking study drug immediately.  See  
Section 8.4.4  for a description of procedures to be followed in case of pregnancy.  
[IP_ADDRESS] Study Drug Administration  
Patients will be administered one capsule from each bottle included in the study drug kit orally once a day 
beginning on Day 1 while the patient remains hospi[INVESTIGATOR_057], as indicated in Table 1.  Each dose of study 
drug should be administered at approximately the same time each day, preferably in the morning.  Patients 
unable to receive oral medications (e.g., due to intubation and/or mechanical ventilation) may receive the 
contents of the capsule through a nasogastric or orogastri c tube flushed with water.   A vomited dose must 
not be replaced.  A double dose ( e.g., missed dose from previous day and dose for current day) must not 
be taken.  
Study number:  S20-[ZIP_CODE]   Page 23 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  [IP_ADDRESS] SARS CoV -[ADDRESS_424375] to satisfy the 
study’s i nclusion criteria.  If feasible  per local clinical care , SARS CoV -[ADDRESS_424376] is requested to be 
collected at Day 15 or End of Treatment, whichever is earlier.  
[IP_ADDRESS] In-person/Telephone Contact  
[CONTACT_342636] a  follow -up on Day 29, regardless of treatment adhe rence and recovery status prior to 
Day 29, and a  safety follow -up 60 days after randomization , which may be conducted by [INVESTIGATOR_2993]-person visit 
(preferable) or telephone call  (if there are quarantine and other restrictions) .  The call will include questions 
on health status including new adverse events, continuing adverse events, hospi[INVESTIGATOR_6042], continued care, 
reinfection or death following exposure to bardoxolone methyl or placebo in the trial.  
[IP_ADDRESS] Adverse Event Collection  
All adverse events will be recor ded as indicated in Table 1.   
[IP_ADDRESS] Clinical Status Assessment  
Clinical status of the patient will be assessed as indicated in Table 1. The assessment will include collection 
of data related to critical events  and other data to support the  safety reporting criteria set by [CONTACT_4318] . An 
11-category ordinal scale  defined in Section [IP_ADDRESS]  will be used to support data collection for the 
exploratory endpoint.  
[IP_ADDRESS] Recovery  Assessm ent 
Each of the following p atient recovery components will be assessed as indicated in Table 4 :   
• Alive (y es/no) 
• Free of respi[INVESTIGATOR_1399] (y es/no) 
• Free of RRT (y es/no) 
[IP_ADDRESS] eGFR 
The eGFR value will be calculated using the Chronic Kidney Disease Epi[INVESTIGATOR_10444] (CKD -
EPI) equation:  
eGFR (mL/min/1.73 m2) = 141 × min (S cr/κ, 1)α × max(S cr/κ, 1)-1.209 × 0.993Age ×  
1.018 [if female] × 1.159 [if black]  
Where the patient’s age on the date of consent is used, S cr is serum creatinine (mg/dL), κ is 0.7 for females 
or 0.9 for males, and α is -0.329 for females or -0.411 for males.  Min indicates the minimum of S cr/κ or 1 
and max indicates the maximum of S cr/κ or 1.   
[IP_ADDRESS] PaO2/FiO2 Ratio 
PaO 2/FiO 2 ratio will be collected as indicated in Table 1 and calculated by [CONTACT_342637] 2 from the arterial 
blood gas and then dividing by [CONTACT_342638] 2 for that oxygen delivery method (0.21 for room air, 0.21 
+ (oxygen flow rate * 0.03) for nasal cannula, 0.80 for non -rebreather mask or the recorded FiO 2 for non -
invasive or invasive ventilation)  (Brown SM et al. Chest 2016;150:307 -13). 
Study number:  S20-[ZIP_CODE]   Page 24 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_424377] of Care Study Procedures  
[IP_ADDRESS] Vital Sign Measurements  
Vital sign measurements include the patient’s heart rate, respi[INVESTIGATOR_1487], and body temperature.  Vital sign 
measurements should be ta ken as indicated in Table 1. Data related to vitals signs will be used to calculate 
a National Early Warning Score (NEWS)  at each assessment . If feasible, vital sign measurements will be 
taken  during  outpatient  study  visits. 
[IP_ADDRESS] Laboratory Assessments  
Samples will be collected for specified clinical chemistry and hemoatology analyses as indicated in Table 
1. If feasible, available laboratory assessments will be reviewed  during  outpatient visits. The analyses will 
include the following:  
• Clinical Chemistry  and biomarkers  
o Comprehensive metabolic panel  
o Lipid panel  
o Cytokines  (if feasible  per local clinical care ) 
o Ferritin  
o Lactate dehydrogenase  
o C-reactive protein  
o Cardiac markers ( Troponin ) 
o B-type natriuretic peptide (BNP)  
• Hematology  
o Complete blood count (CBC)  
o CBC differential  
o Coagulation testing  (including PT, INR, fibrinogen, D -dimer, etc. ) 
[IP_ADDRESS] Chest Imaging  
Chest imaging test performed  as part of standard of care will be reviewed for eligibility. . 
7.2 Study Schedule  
All patients enrolled in the Phase 2 and Phase 3 portions of the trial will follow the same study schedule.  
7.2.1 Screening /Enrollment   
 
Screening/Enrollment Visit (Day -3 to 1) 
• Obtain informed consent of potential participant , or legally authorized representative  verified by 
[CONTACT_342639]. Written and/or electronic signature [INVESTIGATOR_6251].  
• Review m edical history and medications history  to determine eligibility based on inclusion/exclusion 
criteria.  
• Perform medical examinations needed to determine eligibility based on inclusion/exclusion criteria . 
• Verify inclusion/exclusion criteria.  
• Obtain blood or urine  for pregnancy test  if subject is WOCBP . 
• Obtain demographic information, medical history, medication history, alcohol and tobacco use 
history.  
• Review and r ecord vital signs, results of medical examinations, results of laboratory assessment, 
and other assessments  as indicated  in Table 1.   
7.2.2 Intermediate Visits  
[IP_ADDRESS] Visit 1 (Day 1) 
• Verify inclusion/exclusion criteria.  
Study number:  S20-[ZIP_CODE]   Page 25 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  • Administer first dose of the study treatment in ac cordance with Section 6  of protocol.  
• Review and record concurrent medications.  
• Review and record  available  laboratory assessments as indicated in Table 1. 
• Review and record  vital signs, res ults of medical examinations, results of laboratory assessment, 
and other assessments as indicated  in Table 1.   
• Assess clinical status .  
• Record adverse events as reported by [CONTACT_342640] .  
[IP_ADDRESS] Visit 2 (Day 3)  
• Verify study drug wa s admini stered in accordance with Section [ADDRESS_424378] visit . 
• Review and record concurrent medications.  
• Review and record available laboratory assessments as indicated in Table 1. 
• Review and record vital signs, results of medical examinations, results of laboratory assessment, 
and other assessments as indicated in Table 1.   
• Asse ss clinical status.  
• Record adverse events as reported by [CONTACT_145855].  
[IP_ADDRESS] Visit 3 (Day 5)  
• Verify study drug was administered in accordance with Section [ADDRESS_424379] visit  
• Review and recor d concurrent medications.  
• Review and record available laboratory assessments as indicated in Table 1. 
• Review and record vital signs, results of medical examinations, results of laboratory assessment, 
and other assessments as indicated in Table 1.   
• Assess clinical status.  
• Record adverse events as reported by [CONTACT_145855].  
[IP_ADDRESS] Visit 4 (Day 8)  
• Verify study drug was administered in accordance with Section [ADDRESS_424380] visit . 
• Review and record concurrent medications.  
• Review and record available laboratory assessments as indicated in Table 1. 
• Review and record vital signs, results of medical ex aminations, results of laboratory assessment, 
and other assessments as indicated in Table 1.   
• Assess clinical status.  
• Record adverse events as reporte d by [CONTACT_145855].  
[IP_ADDRESS] Visit 5 (Day 11)  
• Verify study drug was administered in accordance with Section [ADDRESS_424381] visit . 
• Review and record concurrent medications.  
• Review and record  availa ble laboratory assessments as indicated in Table 1. 
• Review and record vital signs, results of medical examinations, results of laboratory assessment, 
and other assessments as indicated in Table 1.   
• Asse ss clinical status.  
• Record adverse events as reported by [CONTACT_145855].  
[IP_ADDRESS] Visit 6 (Day 15)  
• Verify study drug was administered in accordance with Section [ADDRESS_424382] visit . 
• Review and rec ord concurrent medications.  
• Review and record  available  laboratory assessments as indicated in Table 1. 
• Review and record vital signs, results of medica l examinations, results of laboratory assessment, 
and other assessments as indicated in Table 1.   
• Assess clinical status.  
Study number:  S20-[ZIP_CODE]   Page 26 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  • Record adverse events as rep orted by [CONTACT_145855].  
[IP_ADDRESS] Visit 7 (Day 22)  
• Verify study drug was administered in accordance with Section [ADDRESS_424383] visit . 
• Review and record concurrent medications.  
• Review and record  available  laboratory assessments as indicated in Table 1. 
• Review and record vital signs, results of medical examinations, results of laboratory assessment, 
and other assessments as indicated in Table 1.   
• Assess clinical status.  
• Record adverse events as reported by [CONTACT_145855].  
[IP_ADDRESS] Visit 8 (Day 29)  
• If patient is receiving treatment  on Day 29, verify study drug was administered in accordance with 
Section [ADDRESS_424384] visit.  
• If patient was discharged prior to Day 29, make arrangements for outpatient follow -up visit.  
• Review and record available laboratory assessments as indicated in Table 1. 
• Review and record vital signs, results of medical examinations, results of laboratory assessment, 
and other assessments as indicated in Table 1.   
• Assess clinical status.  
• Assess recovery status.  
• Record adverse events as reported by [CONTACT_342641].  
[IP_ADDRESS] End of Treatment  Visit (or Day of Recovery  if prior to Day 29 ) 
• Due t o the nature of this visit (end of treatment or day of recovery), study drug will not be 
administered at this visit.  
• Verify study drug was administered in accordance with Section [ADDRESS_424385] visit.  
• Review and re cord concurrent medications.  
• Review and record available laboratory assessments as indicated in Table 1. 
• Review and record vital signs, results of medical examinations, results of laboratory assessment, 
and other assessments as indicated in Table 1.   
• Asse ss clinical status.  
• Assess recovery status.  
• Record adverse events as reported by [CONTACT_145855].  
7.2.3 Final Safety Follow -up 
Final Safety Follow -up (Visit 10, Day 60) 
• Safety follow -up with participant 60 days after randomization . 
• Review and record available laboratory assessments as indicated in Table 1. 
• Review and record vital signs, results of medical examinations, results of laboratory assessment, 
and other assessments as indicated in Table 1.   
• Asse ss clinical status . 
• Assess recovery status.  
• Record adverse events as reported by [CONTACT_145855].  
7.2.4 Withdrawal /Early Termination Visit 
 
Withdrawal /Early Termination  Visit  
• Review and record concurrent medications.  
• Record adverse events as reported by [CONTACT_145855].  
• Assess clinical status.  
• If study treatment is ongoing at time of withdrawal : 
Study number:  S20-[ZIP_CODE]   Page 27 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_424386] vital signs, results of medical examinations, results of laboratory 
assessment, and other assessments as indicated in Table 1.   
Concomitant Medications, Treatments, and Procedures  
All concomitant prescription medications taken during study participation will be recorded on the case report 
forms (CRFs). For this protocol, a prescription medication is defined as a medication that can be prescribed 
only by a properly authorized/licensed clinician. Medications to be reported in the CRF are concomitant 
prescription medications, over -the-counter medications and non -prescription medications.  
7.3 Justification for Sensitive Procedures  
The use of placebo as the comparator will provide an objective assessment of bardoxolone methyl’s 
treatment effect on proportion recovered in patients with COVID -19.   
7.3.1 Precautionary Medications, Treatments, and Procedures  
The investigator may choose to dec rease the patient’s dose to a lower  dose ( e.g., 20 mg to 10  mg), if 
clinically indicated.  Reasons for dose de -escalation should be documented.  Once a patient’s dose has 
been reduced, dose re -escalation back to a higher dose is permitted.  
7.4 Prohibited  Medications, Treatments, and Procedures  
Patient enrolled in other trials of unapproved therapi[INVESTIGATOR_342608].  Given the nature of the clinical situation in patients with COVID -19 and the evolvin g 
status of therapi[INVESTIGATOR_342609], this study will permit  simultaneous enrollment (co-enrollment) in other  
studies .  Permission to co -enroll will be decided on a case by [CONTACT_342642], mechanistic incompatibility  and ability to adjudicate serious adverse events. Data on co -
enrollment will be captured in the EDC and SAE/AE in this subset will be tracked through the length of the 
trial (see section 8.4.1).  Moreover, subgroup analysis will be performed in the cohort  of patients co -enrolled 
in other trials (see section 10.4.8).  In general, co -enrollment will be permitted unless there are safety 
concerns, mechanistic incompatibility or inability to adjudicate serious adverse events  and will be decided 
on a case by [CONTACT_342643] e basis .   
 
Concomitant use with strong CYP3A4 inhibitors is prohibited.  If a strong CYP3A4 inhibitor is medically 
necessary, study drug should be temporarily discontinued.  Concomitant study drug use with moderate 
CYP3A4 inhibitors should be avoided whenever possibl e, and switching to an alternative agent should be 
considered.   
8 Assessment of Safety  
8.1 Specification of Safety Parameters   
The following safety endpoints will be assessed during the study:  
• All adverse events that are serious , unexpected,  and have a reasonab le possibility of having 
been related to the study  drug  
• All unexpected deaths  
8.1.1 Definition of Adverse Events (AE)  
An adverse event  (AE) is any symptom, sign, illness or experience that develops or worsens in severity 
during the course of the study.   Intercurrent illnesses or injuries should be regarded as adverse 
events.   Abnormal results of diagnostic procedures are considered to be adverse events if the abnormality:  
Study number:  S20-[ZIP_CODE]   Page 28 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  • results in study withdrawal  
• is associated with a serious adverse event  
• is associated  with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests  
• is considered by [CONTACT_1372]  
8.1.2 Definition of Serious Adverse Events (SAE)  
Serious Adverse Event  
Adverse events are classified as  serious or non -serious.  A serious adverse event  is any AE that is:  
• fatal 
• life-threatening  
• requires or prolongs hospi[INVESTIGATOR_4408]  
• results in persistent or significant disability or incapacity  
• a congenital anomaly or birth defect  
• an important medical event  
 
Important medical events are those that may not be immediately life threatening, but are clearly of major 
clinical significance. They may jeopardize the subject, and may require intervention to prevent one of the 
other serious outcomes noted above. For example, drug overdose or abuse, a seizure that did not result in 
in-patient hospi[INVESTIGATOR_059], or intensive treatment of bronchospasm in an emergency department would 
typi[INVESTIGATOR_15355].  
 
All adverse events that do not meet any of the crit eria for serious should be regarded as non-serious 
adverse events .  
8.1.3 Definition of Unanticipated Problems (UP)  
Unanticipated Problems Involving Risk to Subjects or Others  
Any incident, experience, or outcome that meets all of the following criteria:  
• Unexpe cted in nature, severity, or frequency   (i.e. not described in study -related documents such 
as the IRB -approved protocol or consent form, the investigators brochure, etc)  
• Related or possibly related to participation in the research  (i.e. possibly related m eans there is a 
reasonable possibility that the incident experience, or outcome may have been caused by [CONTACT_9156])  
• Suggests that the research places subjects or others at greater risk of harm  (including physical, 
psychological, economic, or social harm).  
8.2 Classification of an Adverse Event  
8.2.1 Severity of Event  
Severity for each adverse event will be graded using the NCI Common Terminol ogy Criteria for Adverse 
Events ( CTCAE)  system . All adverse events will be recorded :  
 
• Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
• Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting a ge-appropriate 
instrumental activ ities of daily living . 
• Grade 3: Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_8942]; disabling; limiting self care activities of daily living . 
• Grade 4: Life -threatening conseque nces; urgent intervention indicated.  
• Grade 5: Death related to AE.  
 
Study number:  S20-[ZIP_CODE]   Page 29 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  8.2.2 Relationship to Study Agent  
For all collected AEs, the clinician who examines and evaluates the participant will determine the AE’s 
causality based on temporal relationship and his/her clinical judgment. The degree of certainty about 
causality will be graded using the categories below.  
• Definitely Related  – The event follows: (a) a reasonable, temporal sequence from study drug or a 
study procedure; and (b) cannot be explained by t he known characteristics of the participant’s 
clinical state or other therapi[INVESTIGATOR_014]; and (c) evaluation of the participant’s clinical state indicates to the 
investigator that the experience is definitely related to study procedures.  
• Probably Related  – The even t should be assessed following the same criteria for “Definitely 
Related”. If in the investigator’s opi[INVESTIGATOR_274365], then is 
can be assessed as “probably” related . 
• Possibly Related  – The event should be assessed  following the same criteria for “Definitely 
Related”. If in the investigator’s opi[INVESTIGATOR_274365], then it 
can be assessed as “possibly” related . 
• Probably Not R elated  – The event occurred while the participant was receiving study 
drug/intervention or undergoing study procedures but can reasonably be explained by [CONTACT_342644]’s clinical state or other therapi[INVESTIGATOR_014].  
• Definitely Not Related  – The event is definitely produced by [CONTACT_2299]’s clinical state or by 
[CONTACT_43593][INVESTIGATOR_342610].  
• Uncertain Relationship : The event does not meet any of the criteria previously outlined.  
8.2.3 Expectedness  
The investigator  responsible  at each local site  will be responsible for determining whether an AE is expected 
or unexpected. An AE will be considered unexpected if the nature, severity, or frequency of the event is not 
consistent with the risk information previously  described for the stud y agent.  
 
There are a plethora of adverse events expected that will be related to COVID -19 infection and not the use 
of the drug, including death. Some examples of expected COVID -19 related AE include (but not limited to) 
death, intubation, need for presso rs, mechanical circulatory support, resuscitated cardiac arrest, acute 
kidney injury, infection (non COVID -19), LFTs >5x ULN, disseminated intravascular coagulation, and 
symptomatic venous thromboembolism.   
8.3 Time Period and Frequency for Event Assessment an d Follow -Up 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and 
interviews of a study participant presenting for medical care, or upon review by a study monitor. All adverse 
events will be captured on the app ropriate  eCRF . Information to be collected includes event description, 
time of onset, clinician’s assessment of severity, relationship to study product (assessed only by [CONTACT_214527] a diagnosis), and time of resolution/stabilization of the event. All AEs will 
be followed to adequate resolution.  
 
Any medical condition that is present at the time that the participant is screened will be considered as 
baseline and not reported as an AE. However, if the study part icipant’s condition deteriorates at any time 
during the study, it will be recorded as an AE. UPs will be recorded in the data collection system throughout 
the study.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duratio n of the event 
at each level of severity to be performed. AEs characterized as intermittent require documentation of onset 
and duration of each epi[INVESTIGATOR_1865].  
 
The PI [INVESTIGATOR_342611] 7 (for non -serious AEs) or 30 days (for SAEs) after the last day of study participation. At each study 
visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit. Events will be followed 
for outcome informatio n until resolution or stabilization.   
 
Study number:  S20-[ZIP_CODE]   Page 30 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_424387] to report any subsequent event(s) that the subject, or the subject’s 
personal physician, believes might reasonably be related to participation in this study.  The investigator 
should notify the study sponsor of any dea th or adverse event occurring at any time after a subject has 
discontinued or terminated study participation that may reasonably be related to this study.  The sponsor 
should also be notified if the investigator should become aware of the development of ca ncer or of a 
congenital anomaly in a subsequently conceived offspring of a subject that has participated in this study  
that may reasonably be related to this study.    
8.4 Reporting Procedures  – Notifying the IRB  
8.4.[ADDRESS_424388] a reasonable possibility 
of having been related to a study drug (from time of administration of the first dose at the Day 1 visit until 
the final visit indicated in Table 4) must be report ed. 
The investigator is responsible for reporting all SAEs that are observed or reported by [CONTACT_342645] (from the time of administration of the first dose of study drug until the final visit indicated in Table 
1, as appropriate ).  Additional information from the investigator may be requested to ensure the timely 
completion of accurate safety reports.   Serious adverse events related to COVID -[ADDRESS_424389] be followed to resolution or until the investigator 
deems the event to be chronic or the patient to be stable.  The investigator may be contact[CONTACT_342646].   
 
A summary of SAEs and AEs experie nced by [CONTACT_342647] -enrolled in other  clinical trials will be reported to 
the IRB  on a monthly basis. The report will  include a sta tement from the PI [INVESTIGATOR_342612] -enrolled group as compared to the not co -enrolled group.  
8.4.2 Unanticipated Problem Reporting  
Incidents or events that meet the criteria for U Ps in Section 8.1.3  require the cre ation and completion of an 
UP report form. It is the site investigator’s responsibility to report UPs to their IRB and to the DCC /study 
sponsor. The UP report will include the following information:  
 
• Protocol identifying information: protocol title and num ber, PI’s name, and the IRB project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP;  
• A description of any changes t o the protocol or other corrective actions that have been taken or are 
proposed in response to the UP.  
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
 
• UPs that are SAEs will be reported to the IRB and t o the DCC/study sponsor within 24 hours of the 
investigator becoming aware of the event.  
• Any other UP will be reported to the IRB and to the DCC/study sponsor within [ADDRESS_424390] practice one of the following acceptable methods of birth control:  
Study number:  S20-[ZIP_CODE]   Page 31 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  • Use double barrier contraception method defined as male use of a condom and female use of 
a barrier method (e.g., contraceptive sponge, spermicidal jelly or cream, diaphragm [always 
use with spermicidal jelly/cream]);  
• Use of hormonal contraceptives (oral, parenteral, vaginal, or transdermal);  
• Use of an intrauterine device;  
• Abstain  from sexual intercourse completely.     
Males who have female partners of childbearing potential must practice one of the following methods of 
birth control  during the study, and for 30 days following  administration of the final dose of study medication : 
• Have had a vasectomy;  
• Use double barrier contraception method, defined as male use of a condom and female use of 
a barrier method (e.g., contraceptive sponge, spermicidal jelly or cream, diaphragm [alw ays 
use with spermicidal jelly/cream]);  
• Partner use of an intrauterine device;  
• Partner use of hormonal contraceptives (oral, parenteral, vaginal or transdermal);  
• Abstain from sexual intercourse completely.     
WOCBP  must be instructed to contact [CONTACT_342648] 
(e.g., late or missed menstrual period).  Male patients must be instructed to contact [CONTACT_53022] a 
sexual partner suspects she may be pregnant.  
If a patient or investigator suspects that th e patient may be pregnant, the study drug must be withheld until 
the results of a serum pregnancy test are available.  If the serum pregnancy test confirms the pregnancy, 
the patient must permanently discontinue taking study drug.  The investigator must im mediately report to 
the Reata Medical Monitor a pregnancy associated with study drug exposure.  The early discontinuation 
protocol -required procedures outlined for End -of-treatment and Follow -up visits must be performed on the 
patient.  
Pregnancy is not co nsidered an AE; however, the investigator must follow a pregnant patient, or the 
pregnant female partner of a male patient (if consenting), and report follow -up information regarding the 
course of the pregnancy, including perinatal and neonatal outcome.  I nfants resulting from such 
pregnancies should be followed for a minimum of [ADDRESS_424391] be considere d SAEs and will require additional reporting in the 
eCRF and reported as a serious AE:  
• Congenital anomaly/birth defect;  
• Stillbirth;  
• Spontaneous miscarriage.  
8.5 Reporting Procedures – Notifying the Study Sponsor  
The study clinician will complete a SAE Form wit hin the following timelines:  
 
• All unexpected deaths and immediately life -threatening events, will be recorded on the SAE Form 
and submitted to the DCC/study sponsor within [ADDRESS_424392] information.  
• Other SAEs regardless of relationship will be submitted to the DCC/study sponsor within 72 hours 
of site awareness.  
 
Study number:  S20-[ZIP_CODE]   Page 32 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  All SAEs will be followed until satisfactory resolution or until the site investigator deems the event to be 
chronic or the ad herence to be stable. Other supporting documentation of the event may be requested by 
[CONTACT_15791]/study sponsor and should be provided as soon as possible.  
 
As a follow -up to the initial report, within the following 48 hours of awareness of the event, the inv estigator 
shall provide further information, as applicable, on the unanticipated event or the unanticipated problem in 
the form of a written narrative.  Significant new information on ongoing unanticipated adverse effects shall 
be provided promptly to the study sponsor.  
8.6 Reporting Procedures – Notifying the FDA  
The study sponsor is required to report certain study events in an expedited fashion to the FDA.  These 
mandatory written notifications of adverse events are referred to as IND safety reports.  
 
The following describes the IND safety reporting requirements  by [CONTACT_342649]:  
 
• As soon as possible but no later than  7 calendar days  
Any adverse experience  that is : 
– suspecte d, and 
– unexpected , and 
– fatal or life -threatening  
 
• As soon as possible but no later than  15 calendar day s 
Any adverse experience  that is : 
– suspected , and 
– unexpected , and 
– serious, but not fatal or life -threatening  
-or- 
– a previous adverse event that was not initially deemed reportable but is later found to fit the 
criteria for reporting (reporting within 15 cal endar days from when event was deemed 
reportable).  
 
Definitions:  
• Suspected: there is reasonable possibility that the drug caused the adverse event. For the purposes 
of IND safety reporting, ‘reasonable possibility’ means there is evidence to suggest a caus al 
relationship between the drug and the adverse event.  
• Unexpected: refers to an event or reaction that is not listed in the investigator’s brochure or is not 
listed at the specificity or severity that has not been observed / is not consistent with the ri sk 
information described in the IND application.  
• Life-threatening: the sponsor determines that adverse event or suspected adverse reaction is 
considered life -threatening if its occurrence places the participant at immediate risk of death.  
 
Note: Serious adverse events related to COVID -19 infections will not be reported to the FDA unless it 
meets the criteria above. There is a plethora of adverse events expected in the patient population being 
evaluated that will be related to the COVID -19 infectio n and not associated with the use of bardoxolone 
methyl. These adverse events include death, which is expected in severe cases of COVID -19. 
 
Follow-up Safety Reporting  
Sponsors are also required to identify in IND safety reports all previous reports concer ning similar adverse 
events and to analyze the significance of the current event in light of the previous reports.  
 
Reporting Process  
Adverse events may be submitted on FDA Form 3500A (MEDWATCH Form : 
https://www.fda.gov/media/[ZIP_CODE]/download ), or in a narrative format. If supplied as in a narrative format, 
the minimum information to be supplied is noted above at the beginning of section 8.3.  
Study number:  S20-[ZIP_CODE]   Page 33 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019   
Study Halting Rules 
At a designated time during Phase 3 of the trial ( ~40% and ~70% of projected sample size has  accrued) 
interim analysis will be performed  for safety, harm and futility . Safety and harm stoppi[INVESTIGATOR_342613]-tailed group sequential Z -testing  with three stages a nd boundaries calculated from an O’Brien -
Fleming spending function . Futility stoppi[INVESTIGATOR_342614], two -tailed group sequential 
Z-testing with three stages and boundaries calculated from an O’Brien -Fleming spending function. The 
Executive Committee can request to be unblinded after receiving the recommendation from the DSMB after 
the Phase [ADDRESS_424393] an. 
8.7 Safety Oversight  
It is the responsibility of the Principal Investigator [INVESTIGATOR_16462]/her site.  This 
safety monitoring will include careful assessment and appropriate reporting of adverse events as noted 
above, as well as t he construction and implementation of a site data and safety -monitoring plan.  Medical 
monitoring will include a regular assessment of the number and type of serious adverse events.  All study 
information will be communicated between the PI [INVESTIGATOR_342615] -needed basis via emails, phone 
calls, teleconferences, webinars, and in -person meetings. All attempts will be made to ensure 
communications are timely with respect to the topic of the communication.  
 
Safety oversight will be under the direction of the NYU Langone Health COVID -[ADDRESS_424394] of the trial 
is in compliance with the currently approved protocol/amendment(s), with GCP, and with applicable 
regulatory requirement(s).  
 
• Monitoring for this study will be performed by [CONTACT_342650] . 
• Monitoring will be performed centrally at specified time points throughout the study. For -cause on -
site monitoring w ill be performed when needed.  A random review of certain data points related to 
endpoint, safety, and other key data variables will be performed.  Monitoring related to protocol 
adherence will be performed on an ongoing basis.  
• Details of clinical site mon itoring will be documented in a CMP.  The CMP will describe the frequency 
of monitoring, which data points will be monitored, and the distribution of monitoring reports.  
10 Statistical Considerations  
10.1 Statistical and Analytical Plans  (SAP) 
A formal  SAP detailing the analyses will be developed and finalized prior to database lock  and unblinding 
of the study .  All statistical analyses and data summaries will be performed using SAS® (Version 9. 4 or 
higher) or other validated software.  The SAP will serve as the final arbiter of all statistical analyses.   
Study number:  S20-[ZIP_CODE]   Page 34 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  10.2 Statistical Hypotheses  
10.2.1 Phase 2  
In a given group of 20 subjects the probability of not observing an adverse event when the underlying rate 
is 10%, 20%, 30%, 40%, and 50% is 0.12, 0.01, 0.001, 0, and 0, respectively. This indicates that in a sample 
of 20 subjects, the study is sufficiently sized to observe AEs that occur at a rate of 10% or greater.  
10.2.[ADDRESS_424395] is the “ risk difference ,” which quantifies the 
shift in probability  of recovery resulting from treatment.  A positive risk difference 1 indicates a higher 
proportion of patients recovering in the bardoxolone methyl group relative to placebo.   The null hypothesis 
to be tested is that the risk difference is the same for the placebo and bardoxolone methyl arms and is 
stated as H 0: RD = 0, where RD denotes the risk difference .      
10.3 Analysis Populations  
The following analysis populations will be defined:  
• The i ntent ion-to-treat (ITT)  population includes all randomized patients categorized by [CONTACT_342651] (whether  or not they received study drug).  Efficacy analyses of the 
primary and secondary outcomes will be performed using the ITT population.  
• The safety population includes all patients who received at least one dose of randomized study 
drug. Patients who receive a t least one dose of bardoxolone methyl will be classified in the 
bardoxolone methyl group, and patients who receive at least one dose of placebo and no dose of 
bardoxolone methyl will be classified in the placebo group.  
• Additional analysis populations may be defined in the SAP as appropriate.  
10.4 Description of Statistical Methods  
The following subsections include  brief descriptions of the planned statistical methods.  Full detail of the 
planned analyses will be described in the formal SAP . 
10.4.1 General Approach  
This is a double -blind placebo controlled randomized trial testing a superiority hypothesis with a two -sided 
significance level of 0.05 . Data for this placebo -controlled t rial will be summarized by [CONTACT_342652].  Continuous data will be summarized with number of patients (n), mean, median, 
minimum, maximum, relevant quartiles, standard deviation, coefficient of variation, and geometric mean 
(where applicable).  Categorical data will be summarized using frequency counts and percentages. 
Handling of missing data will be described in the SAP.   
10.4.2 Analysis of the Phase 3 Primary Efficacy Endpoint  
The pri mary efficacy endpoint is recovery, where recovery is defined as meeting all of the following criteria  
at Day 29 : 
• Alive ,  
• Free of respi[INVESTIGATOR_1399], and  
• Free of renal replacement therapy (RRT) . 
Analysis of the Phase [ADDRESS_424396] estimated from  
a generalized linear model analysis  accounting for the stratification  factors of  study center  and mechanical 
venti lation status as covariates .  The pr imary efficacy endpoint will be a covariate -adjusted estimate as 
specified in the Statistical Analysis Plan.   Events will be analyzed and presented as summary tables of 
proportion recovered  with risk differences and 95% confidence intervals (CIs) for the comparison of 
Study number:  S20-[ZIP_CODE]   Page 35 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  bardoxolone methyl to placebo.  The SAP will include additional detail of the planned analyses and 
definitions of sensitivity analyses .   
10.4.3 Analysis of the Secondary /Exploratory  Endpoints  
The secondary endpoints include the following:  
• Change in eGFR  (mL/min/1.73 m2) during treatment  as calculated using the CKD -EPI [INVESTIGATOR_14420].  
• Number of mechanical ventilation -free days . 
The two treatment groups will be compared with respect to the secondary endpoints. The  treatment of 
missing data, and the strategy to preserve the overall Type I error will be described in the SAP .  
10.4.[ADDRESS_424397] results, vital sign measurements,  
and PaO 2/FiO 2 ratio.  All analyses of the safety data will be  performed using the safety analysis set.  
Descriptive statistics are presented by [CONTACT_342653] a nalysis set.   
[IP_ADDRESS] Adverse Events  
The Medical Dictionary for Regulatory Activities (MedDRA) dictionary will be used to classify all AEs 
reported  during the study by [CONTACT_9313] (SOC) and preferred term (PT).  All summary tables will 
include counts of pa tients with treatment -emergent adverse events (TEAEs).  TEAEs are defined as those 
AEs that have an onset time either at or after the start of study drug administration and no more than [ADDRESS_424398] dose of study drug is administered.  An overall  summary of TEAEs will be presented with 
the number and percentage of patients having a TEAE, a serious TEAE, a TEAE leading to study 
discontinuation, a TEAE with an outcome of death, a TEAE related to study drug (definitely, probably, or 
possibly related) , or a severe TEAE.  The overall incidence of TEAEs will be summarized by [CONTACT_342654].  The incidence of serious TEAEs and TEAEs leading to  premature  study discontinuation will be 
summarized in a similar manner.  TEAEs will also be summarized by [CONTACT_764] (mild, moderate, 
or severe), and assessed relationship to study drug with the percentage of patients in each category . TEAEs 
leading to premature study discontinuation, and TEAEs with an outcome of death will also be presented in 
separate listings.  
10.4.[ADDRESS_424399] deviation , and interquartile range  
will be summarized. Categorical variables will be described by [CONTACT_342655] y, with the 
corresponding sample size s. 
10.4.7 Planned Interim Analysis  
[IP_ADDRESS] Safety Review  
A DSMB will be reviewing unblinded data from the study to ensure patient safety.  The DSMB charter will 
describe the scope and frequency  for regularly occurring interim safety reviews .   
10.4.[ADDRESS_424400] , including in the subgroup of  patients co -
enrolled in other trials , as specified in the SAP.    
Study number:  S20-[ZIP_CODE]   Page 36 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  10.4.9 Multiple Comparison/Multiplicity  
This study includes a single primary endpoint .  The two secondary efficacy endpoints will be tested using a 
strategy that preserves the overall Type I error rate.  
10.4.10 Tabulation of Individual Response Data  
Individual patient data will be listed by [CONTACT_342656] . 
10.4.11 Exploratory Analyses  
The SAP will describe exploratory efficacy analyses.  
10.5 Sample Size  
A total sample size of approximately 400 participants  (Phase 2 combined with Phase 3 , or Phase 3 alone , 
depending on unblinding of Phase 2 ) randomized 1:1 using block r andomization  (~200 bardoxolone methyl; 
~200 placebo) is expected to provide approximately 80% power at a two -sided 0.[ADDRESS_424401] a risk difference  of +.14, assuming the following:  
• Follow -up for events for 28 days after randomization ( at Day 29)  
• 2% of patients in each group drop -out prior to Day 29  
• Increase in the probability of recovery from 50% for patients randomized to placebo relative to 
64% of patients randomized to bardoxolone  methyl. 
Under these assumptions , approximately 228  (57%  of the 400 enrolled) will have  recover ed at Day [ADDRESS_424402] the overall type I error rate of the trial. If the DSMB concludes the trial 
should continue to the Phase 3 part, then the phase 2 patients will be included in the phase 3 portion of the 
study.  
  
Table 5 shows effects detectable with 80% power for a total sample size of 400 and a range of prop ortion 
of placebo patients recovered at Day 29.  
 
Table 5. Effects detectable with 80% power for a sample size of n=400 
and a range of proportion of placebo patients recovered  
Placebo Proportion 
Recovered at Day 29  Bardoxolone Proportion 
Recovered at Day 29 Risk 
Difference  
0.350  0.488  0.14 
0.400  0.539  0.14 
0.450  0.590  0.14 
0.500  0.638  0.14 
0.550  0.686  0.14 
0.600  0.732  0.13 
0.650  0.776  0.13 
0.700  0.819  0.12 
0.750  0.861  0.11 
0.800  0.900  0.10 
0.850  0.936  0.09 
0.900  0.969  0.07 
    
Study number:  S20-[ZIP_CODE]   Page 37 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  10.6 Measures to Minimize Bias  
10.6.1 Enrollment/Randomization/Masking Procedures  
An IWRS will be utilized to randomize patients 1:1 to once daily administration of bardoxolone methyl or 
placebo.  Randomization will be performed using block randomization with the following strata : center  and 
invasive mechanical ventilation (i.e., mechanical ventilation with endotracheal intubation) at baseline (yes 
or no).  Enrollment of patients ≥70 years of age may be limited (e.g., comprise no more than 10% of all 
randomized patients) , pending safety review by [CONTACT_342657], investigators, site personnel, laboratories, and study personnel  with direct involvement in the 
conduct of the study or their designees will be blinded to treatment assignments.  To prevent potential bias, 
appropriate measures will be taken to ensure the blind is maintained for the patients and personnel 
mentioned prev iously.  To maintain the blind, investigators will distribute blinded study drug treatment to 
patients as directed by [CONTACT_125070].  Investigators and patients will not be blinded to dose level, but 
will be blinded to treatment assignment (i.e.,  bardoxo lone methyl vs. placebo).  
 
An IWRS will manage treatment assignments and study drug dispens ing.  The only people with direct 
access to treatment assignments prior to database lock will be those individuals who develop and maintain 
the randomization code  and the DSMB .   
 
Following database lock after completion of each phase the study, randomization codes will be released to 
the statistical team for analysis.  
10.6.2 Breaking the Study Blind/Participant Code  
Although bardoxolone methyl has no known antidote, under rare circumstances unblinding may be 
considered medically necessary.  
 
The investigator is encouraged to contact [CONTACT_342658], but the investigator has the right to bre ak the blind (e.g., in the 
event of a serious or life -threatening medical situation).  If unblinding is required, the investigator will utilize 
the IWRS to perform the unblinding.  If a study drug assignment is unblinded, the investigator must describe 
the event that required unblinding in the patient’s source documents.  
 
Patients must permanently discontinue taking study drug if their treatment assignment has been unblinded 
to the investigator (or designee).  Such patients must undergo the same study drug  discontinuation 
procedures as those patients who discontinue taking study drug for other reasons.  Following permanent 
study drug discontinuation due to patient unblind ing, patients should continue with study follow -up through 
their scheduled study assess ments.  
 
Patient treatment assignments must not be unblinded in the case of an AE or SAE, except as described 
above.  
11 Source Documents and Access to Source Data/Documents  
Source data is all information, original records of clinical findings, observations, or other activities in a 
clinical trial necessary for the reconstruction and evaluation of the trial.  Source data are contained in source 
documents.  Examples of these original documents, and data records include: hospi[INVESTIGATOR_1097], clinical and 
office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing 
records, recorded data from automated instruments, copi[INVESTIGATOR_110799], microfi ches, photographic negatives, microfilm or magnetic media, x -rays, 
subject files, and records kept at the pharmacy, at the laboratories, and at medico -technical departments 
involved in the clinical trial. It is acceptable to use CRFs as source documents.  
 
The study case report form (CRF) is the primary data collection instrument for the study.  All data requested 
on the CRF must be recorded , unless otherwise noted in the CRF instructions.   
Study number:  S20-[ZIP_CODE]   Page 38 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019   
Access to study records will be limited to IRB -approved members of the study team. The investigator will 
permit study -related monitoring, audits, and inspections by [CONTACT_1201]/EC, the sponsor, government regulatory 
bodies, and University compliance and quality assurance groups of all study related documents (e.g. source 
docu ments, regulatory documents, data collection instruments, study data etc.).  The investigator will 
ensure the capability for inspections of applicable study -related facilities (e.g. pharmacy, diagnostic 
laboratory, etc.).  
 
Participation as an investigator in this study implies acceptance of potential inspection by [CONTACT_342659].  
12 Quality Assurance and Quality Control  
QC procedures will be implemented beginning with the dat a entry system and data QC checks that will be 
run on the database will be generated. Any missing data or data anomalies will be communicated to the 
site(s) for clarification/resolution.  
 
Following written SOPs, the monitors will verify that the clinical t rial is conducted and data are generated, 
documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory 
requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP).  
 
The investigational site will provide direct access to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_342660].  
13 Ethics/Protection of Human Subjects  
13.[ADDRESS_424403] 
This clinical study was designed and shall be implemented and reported in accordance with the ICH 
Harmonised Tripartite Guidelines for Good Clinical Practice, with applicable local regulations ( e.g., US Code 
of Federal Regulations Title 21, European Dir ective 2001/20/EC), and with the ethical principles laid down 
in the Declaration of Helsinki.  
The principal investigator [INVESTIGATOR_342616] (ICH) for Guidance for Industry on Good C linical Practice (GCP) 
ICH E6(R2)  [https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2
__Step_4 _2016_1109.pdf ] and the principles of the Declaration of Helsinki [ https://www.wma.net/policies -
post/wma -declara tion-of-helsinki -ethical -principles -for-medical -research -involving -human -subjects/ ].  The 
principal investigator [INVESTIGATOR_342617], state, and local 
laws or regulations.  
13.[ADDRESS_424404]  
The pr otocol, informed consent form(s), recruitment materials, and all participant materials will be submitted 
to the IRB for review and approval. Approval of both the protocol and the consent form must be obtained 
before any participant is enrolled. Any amendme nt to the protocol will require review and approval by [CONTACT_118694]. All changes to the consent form will be IRB approved; 
a determination will be made regarding whether previously consented participants need to b e re-consented . 
13.3 Informed Consent Process  
13.3.1 Consent and Other Informational Documents Provided to Participants  
Because the study will be conducted under a [LOCATION_002] Investigational New Drug Application, a signed 
informed consent form, in compliance with T itle 21 of US CFR Part 50, will be obtained from each patient 
before the patient enters the study.  In the event that the participant is not able to provide consent due to 
Study number:  S20-[ZIP_CODE]   Page 39 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_424405] the informed consent process via telephone or video (webex) with use 
of e-consent through REDCap to obtain and document informed consent from the subject or legally 
authorized representative.  
 
An informed consent template may be provided by [CONTACT_342661].  The 
consent must be reviewed by [CONTACT_342662]/EC submission.  Once reviewed, the 
consent will be submitted by [CONTACT_458] [INVESTIGATOR_342618] s or her IRB/EC for review and approval before 
the start of the study.  If the informed consent form is revised during the course of the study, all participants 
affected by [CONTACT_342663]/EC -approved consent form.  
 
Before enrollment, each prospective patient or legally authorized representative will be given a full 
explanation of the study and be allowed to read the approved informed consent form.  Once the principal 
investigator [INVESTIGATOR_342619], the patient will be asked to give consent to participate in the study.   
 
Eligible patients may only be included in the study after providing IRB/EC -approve d informed consent.  
Informed consent must be obtained before conducting any study -specific procedures (i.e., all of the 
procedures described in the protocol).  The process of obtaining informed consent must be documented in 
the patient source documents.  
 
The principal investigator [INVESTIGATOR_53473] a copy of the informed consent form (signed copy to be 
provided per applicable law) to the patient or legally authorized representative.  The original form will be 
maintained in the patient’s medical rec ords at the site.  
13.3.2 Consent Procedures and Documentation  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study 
and continues throughout the individual’s study participation. Extensive discussion of ris ks and possible 
benefits of participation will be provided to the participants and their families. Consent forms will be IRB -
approved and the participant will be asked to read and review the document. The investigator will explain 
the research study to the  participant and answer any questions that may arise. All participants will receive 
a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks 
of the study and of their rights as research participants. Part icipants will have the opportunity to carefully 
review the written consent form and ask questions prior to signing. The participants should have the 
opportunity to discuss the study with their surrogates or think about it prior to agreeing to participate. The 
participant will sign the informed consent document prior to any procedures being done specifically for the 
study. The participants may withdraw consent at any time throughout the course of the trial. A copy of the 
signed informed consent document will  be given to the participants for their records. The rights and welfare 
of the participants will be protected by [CONTACT_132441].  
 
A copy  of the signed informed consent document will be stored in the subject’s research record. The 
consent process, including the name [CONTACT_21811], will be thoroughly documented in 
the subject’s research record.  Any alteration to the standard consent process (e.g. use of a translator, 
consent from a legally authorized representative, consent document presented orally, etc.) and the 
justification for such alteration will likewise be documented .  
13.[ADDRESS_424406] of 1996 (HIPAA).  Those regulations require a signed 
subject authorization in forming the subject of the following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why  
• Who will use or disclose that information  
• The rights of a research subject to rev oke their authorization for use of their PHI.  
Study number:  S20-[ZIP_CODE]   Page 40 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_424407] vital status (i.e. that the subject is alive) at the end of their scheduled study period.  
 
Participant confidentiality is  strictly held in trust by [CONTACT_3486], their staff, and the 
sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples in addition 
to the clinical information relating to participants. Therefor e, the study protocol, documentation, data, and 
all other information generated will be held in strict confidence. No information concerning the study or the 
data will be released to any unauthorized third party without prior written approval of the sponso r. 
 
The study monitor, other authorized representatives of the sponsor, representatives of the IRB or 
pharmaceutical company supplying study product may inspect all documents and records required to be 
maintained by [CONTACT_093], including but not limi ted to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and 
pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
 
The study participant’s contact [CONTACT_342664]. At the end of the study, all records will continue to be kept in a secure location for as long a 
period as dictated by [CONTACT_46202].  
 
Study participant research data, which is for purposes  of statistical analysis and scientific reporting, will be 
transmitted to and stored at NYU Langone Medical Center . This will not include the participant’s contact [CONTACT_10415]. Rather, individual participants and their research data will be identified by a unique 
study identification number. The study data entry and study management systems used by [CONTACT_342665]. At the end of 
the study, all study databas es will be de -identified and archived at the NYU Langone Medical Center . 
 
[ADDRESS_424408] Keepi[INVESTIGATOR_007]  
14.1 Data Collection and Management Responsibilities  
 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site PI. 
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the 
data reported.  
 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of 
data. Data reported in the eCRF derived from source documents should be consistent with the source 
documents or the discrepancies should be explained and captured in a progress note and maintained in 
the participant’s official electronic study record.  
 
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical 
laboratory data will be entered into a [ADDRESS_424409] protection and internal 
quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or 
inaccurate. Clinical data will be entered directly from the source documents.  
14.2 Study Records Retention  
Study documents  will be retained for the longer of 3 years after close -out, 5 years after final 
reporting/publication, or [ADDRESS_424410] approval of a marketing application  is approved for the drug 
for the indication for which it is being investigated  or 2 years after the investigation is discontinu ed and FDA 
is notified if no application is to be filed or if the application has not been approved for such indication. No 
Study number:  S20-[ZIP_CODE]   Page 41 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  records will be destroyed without the written consent of the sponsor, if applicable.  It is the responsibility of 
the sponsor to inform the investigator when these documents no longer need to be retained.  
14.3 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol  or GCP  requirements. The 
noncompliance ma y be either on the part of the participant, the investigator, or the study site staff. As a 
result of deviations, corrective actions are to be developed by [CONTACT_3483].  
 
It is the responsibility of the site PI/study staff to use continuous vigilance to identify and report deviations 
within [ADDRESS_424411] be reported to the local IRB per their guidelines. The site PI/study staff is 
responsible for knowing and adhering to their IRB requirements. Further details about the handling of 
protocol deviations will be included in the MOP.  
14.[ADDRESS_424412] of this trial will be disclosed and managed. Furthermore, 
Study number:  S20-[ZIP_CODE]   Page 42 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_424413] with this study (patent ownership, royalties, or financial gain 
greater than the minimum allowable by [CONTACT_342666] n, etc.) must have the conflict reviewed by [CONTACT_46205] (CIMU) with a Committee -sanctioned conflict management 
plan that has been reviewed and approved by [CONTACT_28833]. All 
NYULMC investigators will follow the applicable conflict of interest policies.   
Study number:  S20-[ZIP_CODE]   Page 43 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  18 References  
Aleksunes LM, Goedken MJ, Rockwell CE, Thomale J, Manautou JE, Klaassen CD. 
Transcriptional regulation of renal cytoprotective genes by [CONTACT_342667]2 and its potential use as  a 
therapeutic target to mitigate cisplatin -induced nephrotoxicity. J Pharmacol Exp Ther. 
2010;335(1):2 -12. 
Aminzadeh MA, Reisman SA, Vaziri ND, et al. The synthetic triterpenoid RTA dh404 (CDDO -
dhTFEA) restores endothelial function impaired by [CONTACT_342668] 2 activity in chronic kidney 
disease.  Redox Biol 2013;1:527 -31. 
Aminzadeh MA, Reisman SA, Vaziri ND, Khazaeli M, Yuan J, Meyer CJ. The synthetic 
triterpenoid RTA dh404 (CDDO -dhTFEA) restores Nrf2 activity and attenuates oxidative stress, 
inflammation, and  fibrosis in rats with chronic kidney disease. Xenobiotica. 2014;44(6):570 -8. 
Auletta JJ, Alabran JL, Kim BG, Meyer CJ, Letterio JJ. The synthetic triterpenoid, CDDO -Me, 
modulates the proinflammatory response to in vivo lipopolysaccharide challenge. J Inte rferon 
Cytokine Res. 2010;30(7):497 -508. 
Brown SM, Grissom CK, Moss M, Rice TW, Schoenfeld D, Hou PC, Thompson BT, Brower RG , 
and NIH/NHLBI PETAL Network Collaborators. Nonlinear imputation of Pao2/Fio2 from 
Spo2/Fio2 among patients with acute respi[INVESTIGATOR_1505]. Chest. 2016;150(2):[ADDRESS_424414]. 2016;243:[ADDRESS_424415]. Sci Rep. 2018;8(1):[ZIP_CODE].  
Chen T, Mou Y, Tan J, Wei L, Qiao Y, Wei T, et al. The protective effect of CDDO -Me on 
lipopolysaccharide -induced acute  lung injury in mice. Int Immunopharmacol. 2015;25(1):55 -64. 
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epi[INVESTIGATOR_103181] 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The 
Lancet. 2020;395([ZIP_CODE]):[ADDRESS_424416] Circumference and Glycemic Control in Obese 
Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidne y Disease. J Diabetes 
Complications 2018;32(12):1113 -1117. 
Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, Inker LA, et al. Bardoxolone 
Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 
Diabetes: Post -Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic 
Kidney Disease and Type 2 Diabetes Study. Am J Nephrol. 2018;47(1):[ADDRESS_424417], et al. Bardoxolone methyl 
analogs RTA 405 and dh404 are  well tolerated and exhibit efficacy in rodent models of Type 2 
diabetes and obesity. Am J Physiol Renal Physiol. 2013;304(12):F1438 -F46. 
Study number:  S20-[ZIP_CODE]   Page 44 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Chin MP, Reisman SA, Bakris GL, O'Grady M, Linde PG, McCullough PA, et al. Mechanisms 
contributing to adverse cardiova scular events in patients with type 2 diabetes mellitus and stage 4 
chronic kidney disease treated with bardoxolone methyl. Am J Nephrol. 2014;39(6):499 -508 
de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 
chronic kidney disease.  N Engl J Med 2013;369:[ADDRESS_424418], Bumeister R, et al. The synthetic triterpenoid, RTA 405, increases the 
glomerular filtration rate and reduces angiotensin II -induced contraction of glomerular mesangial 
cells.  Kidney Int 2013;83:[ADDRESS_424419] and its importance in cellular bioenergetics. Biochem Soc 
Trans. 2015;43(4):602 -10. 
Dinkova-Kostova AT, Liby [CONTACT_342669], Stephenson KK, et al. Extremely potent triterpenoid inducers of 
the phase 2 response: correlations of protection against oxidant and inflammatory stress.  Proc Natl 
Acad Sci [LOCATION_003] 2005;102:4584 -9. 
Espi[INVESTIGATOR_342620], González PA, Kalerg is AM. Modulation of Antiviral Immunity by [CONTACT_342670] -1. Am J Pathol. 2017;187(3):487 -93. 
Fanelli V, Fiorentino M, Cantaluppi V, Gesualdo L, Stallone G, Ronco C, et al. Acute kidney 
injury in SARS -CoV-2 infected patients. Crit Care. 2020;24(1):155.  
Ferguson DA, Wigley WC, Heiss E. Bardoxolone Methyl (BARD) Improves Markers of 
Endothelial Function in Cultured Cells. Poster American Society of Nephrology (ASN) 2010  
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus 
Disease 2019 in China. N Engl J Med. 2020;382(18):1708 -20. 
Hisamichi M, Kamijo -Ikemori A, Sugaya T, Hoshino S, Kimura K, Shibagaki Y. Role of 
bardoxolone methyl, a nuclear factor erythroid 2 -related factor 2 activat or, in aldosterone - and salt-
induced renal injury. Hypertens Res. 2018;41(1):[ADDRESS_424420] -in-human trial 
of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Cli n Cancer Res. 
2012 Jun 15;18(12):3396 -406 
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 
2019 novel coronavirus in Wuhan, China. Lancet. 2020;395([ZIP_CODE]):497 -506. 
Keleku-Lukwete N, Suzuki M, Otsuki A, Tsuchida  K, Katayama S, Hayashi M, et al. Amelioration 
of inflammation and tissue damage in sickle cell model mice by [CONTACT_342667]2 activation. Proc Natl Acad 
Sci U S A. 2015;112(39):[ZIP_CODE] -74. 
Kulkarni AA, Thatcher TH, Hsiao HM, Olsen KC, Kottmann RM, Morrissette J, et al. The 
triterpenoid CDDO -Me inhibits bleomycin -induced lung inflammation and fibrosis. PLoS One. 
2013;8(5):e63798.  
Lee D-F, Kuo H -P, Liu M, et al. KEAP1 E3 ligase -mediated downregulation of NF -kB signaling 
by [CONTACT_342671]ß.  Molecular Cell 2009;36:131 -40. 
Study number:  S20-[ZIP_CODE]   Page 45 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Liu M, Reddy NM, Higbee EM, Potteti HR, Noel S, Racusen L, et al. The Nrf2 triterpenoid 
activator, CDDO -imidazolide, protects kidneys from ischemia -reperfusion injury in mice. Kidney 
Int. 2014;85(1):134 -41. 
Liu Y, Zhang C, Huang F, Yang Y, Wang F, Yuan J, et al. 2019-novel coronavirus (2019 -nCoV) 
infections trigger an exaggerated cytokine response aggravating lung injury. chinaxiv. 
2020:202002.[ZIP_CODE].  
Nagashima R, Kosai H, Masuo M, Izumiyama K, Noshikawaji T, Morimoto M, et al. Nrf2 
Suppresses Allergic Lung I nflammation by [CONTACT_342672] 2 Innate Lymphoid Cell 
Response. J Immunol. 2019;202(5):1331 -9. 
Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The Novel Coronavirus 2019 epi[INVESTIGATOR_342621]. Kidney Int. 2020;97(5):[ADDRESS_424421] of bardoxolone methyl 
on glomerular filtration rate in diabetic kidney disease patients (TSUBAKI study): a randomized 
clinical trial. Kidney International Reports. 2020; In press.  
Nagasu H, Sogawa Y, Kidokoro K,  Itano S, Yamamoto T, Satoh M, et al. Bardoxolone methyl 
analog attenuates proteinuria -induced tubular damage by [CONTACT_342673]. 
FASEB J. 2019;33(11):[ZIP_CODE] -63. 
Nichols DP, Ziady AG, Shank SL, Eastman JF, Davis PB. The triterpenoid CDDO l imits 
inflammation in preclinical models of cystic fibrosis lung disease. Am J Physiol Lung Cell Mol 
Physiol. 2009;297(5):L828 -36. 
Nio Y, Sasai M, Akahori Y, Okamura H, Hasegawa H, Oshima M, et al. Bardoxolone methyl as a 
novel potent antiviral agent again st hepatitis B and C viruses in human hepatocyte cell culture 
systems. Antiviral Res. 2019;169:104537.  
Osburn WO & Kensler TW. Nrf2 signaling: An adaptive response pathway for protection against 
environmental toxic insults.  Mutat Res 2008;669:31 -9. 
Osburn WO, Yates MS, Dolan PD, Chen S, Liby [CONTACT_342669], Sporn MB, et al. Genetic or pharmacologic 
amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicol Sci. 
2008;104(1):[ADDRESS_424422] 
of Nrf2/ARE pathway, exerts potent anti -rotaviral efficacy in vitro. Antiviral Res. 2019;161:53 -
62. 
Pei X, Zhang XJ, Chen HM. Bardoxolone treatment alleviates lipopolysaccharide (LPS) -induced 
acute lung injury through su ppressing inflammation and oxidative stress regulated by [CONTACT_342667]2 
signaling. Biochem Biophys Res Commun. 2019;516(1):[ADDRESS_424423], et al. Bardoxolone methyl and kidney function in CKD with type 
2 diabetes.  N Engl J Med 2011;365:327 -36. 
Pergola P, Acharya A, Appel G, Ahmed A, Betts J, et al. Safety and efficacy of bardoxolone methyl 
in patients with rare chronic kidney dsieases. Poster Euro pean Renal Association – European 
Dialysis and Transplant Association (ERA -EDTA) 2019.  
Study number:  S20-[ZIP_CODE]   Page 46 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_424424] hyperoxic acute lung injury in 
mice. Am J Respir Crit Care Med. 2009;180(9):867 -74. 
Robles L, Vaziri ND, Li S, Masuda Y, Takasu C, Takasu M, et al. Synthetic Triterpenoid RTA 
dh404 (CDDO -dhTFEA) Ameliorates Acute Pancreatitis. Pancreas. 2016;45(5):720 -9. 
Rojas-Rivera J, Ortiz A, Egido J. Antioxidants in kidney diseases: The impact of bardoxolone 
methyl.  Int J Nephrol 2012;2012:1 -11. 
Rothan HA, Zhong Y, Sanborn MA, Teoh TC, Ruan J, Yusof R , et al. Small molecule grp94 
inhibitors block dengue and Zika virus replication. Antiviral Res. 2019;171:104590.  
Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, et al. COVID-19, 
cytokines and immunosuppression: what can we lear n from severe acute respi[INVESTIGATOR_7686]? 
Clin Exp Rheumatol. 2020;38(2):337 -42. 
Shao J, Huang J, Guo Y, Li L, Liu X, Chen X, et al. Up-regulation of nuclear factor E2 -related 
factor 2 (Nrf2) represses the replication of SVCV. Fish & Shellfish Immunology. 2016;58:[ADDRESS_424425] 
Health Sci Int. 2015;2:22 -34. 
Tan SM, Sharma A, Stefanovic N,  Yuen DY, Karagiannis TC, Meyer C, et al. Derivative of 
bardoxolone methyl, dh404, in an inverse dose -dependent manner lessens diabetes -associated 
atherosclerosis and improves diabetic kidney disease. Diabetes. 2014;63(9):[ADDRESS_424426] iron nitrilotriacetate (FeNTA) -induced nephrotoxicity.  Toxicol Appl Pharmacol 
2008;231:[ADDRESS_424427] by [CONTACT_342674] (CDDO -Im and CDDO -Me) for 
protection from LPS -induced inflammatory response and reactive oxygen species in human 
peripheral blood mononuclear cells and neutrophils. Antioxid Redox Signal. 20 07;9(11):1963 -70. 
Thimmulappa RK, Scollick C, Traore K, Yates M, Trush MA, Liby [CONTACT_342669], et al. Nrf2-dependent 
protection from LPS induced inflammatory response and mortality by [CONTACT_342675] -Imidazolide. 
Biochem Biophys Res Commun. 2006;351(4):883 -9. 
Vázquez N, Greenwe ll-Wild T, Marinos NJ, Swaim WD, Nares S, Ott DE, et al. Human 
immunodeficiency virus type 1 -induced macrophage gene expression includes the p21 gene, a 
target for viral regulation. J Virol. 2005;79(7):4479 -91. 
Wu QQ, Wang Y, Senitko M, et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and 
increases expression of protective genes Nrf2, PPARgamma, and HO -1.  Am J Physiol Renal 
Physiol 2011;300:F1180 -F1192. 
Wu J, Liu X, Fan J, Chen W, Wang J, Zeng Y, et al. Bardoxolone methyl (BARD) ameliorates 
aristolochic acid (AA) -induced acute kidney injury through Nrf2 pathway. Toxicology. 
2014;318:22 -31. 
Study number:  S20-[ZIP_CODE]   Page 47 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Wu T, Ye Y, Min SY, Zhu J, Khobahy E, Zhou J, et al. Prevention of murine lupus nephritis by 
[CONTACT_342676] a synth etic triterpenoid. Arthritis 
Rheumatol. 2014;66(11):3129 -39. 
Wyler E, Franke V, Menegatti J, Kocks C, Boltengagen A, Praktiknjo S, et al. Single-cell RNA -
sequencing of herpes simplex virus 1 -infected cells connects NRF2 activation to an antiviral 
program. Nat Commun. 2019;10(1):4878.  
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill 
patients with SARS -CoV-2 pneumonia in Wuhan, China: a single -centered, retrospective, 
observational study. Lancet Respir Med. 2020.  
Zhang JH, Yang X, Chen YP, Zhang JF, Li CQ. Nrf2 Activator RTA -[ADDRESS_424428] Ozone -
Induced Acute Asthma Exacerbation by [CONTACT_342677] γδT17 Cells. Inflammation. 
2019;42(5):1843 -56. 
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical cours e and risk factors for mortality of 
adult inpatients with COVID -19 in Wuhan, China: a retrospective cohort study. Lancet. 
2020;395([ZIP_CODE]):1054 -62. 
  
Study number:  S20-[ZIP_CODE]   Page 48 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as aut horized in writing by [CONTACT_110810]: 11 January 2019  19 Schedule of Events  
Study number:  S20-[ZIP_CODE]   Page 49 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as aut horized in writing by [CONTACT_110810]: 11 January 2019  Table 1: Schedule of Assessments   
Assessment  Screening  Day 1a Day 3 Day 5 Day 8 Day 11 Day 15 Day 22 Day 29k End of 
Treatment  j Day 60 
Safety 
Follow-upb 
Informed consent  X           
Inclusion/ exclusion  X           
Demographics and baseline 
disease characteristics  X           
Chest imaging  Xh           
Medical history  X           
Pregnancy test for WOCBPe X           
Concomitant medications  X Xb,c X X X X X X  X  
Vital sign measurements  X Xd,e X X X X X X X X X 
Study drug administration   ----------------------------------------------------------------------- X------------------------------------------------------------------------    
Adverse event collection   X f X X X X X X X X X 
Recovery status assessment          X X X 
Clinical status assessment  X Xf,g X X X X X X X X X 
Comprehensive metabolic 
panel  X X c  X X   X X X X 
Lipid panel   X c  X X   X  X  
Cytokinesl  X c  X X   X  X  
Ferritin   X c  X X   X  X  
Lacate dehydrogenase (LDH)   X c  X X   X  X  
C-reactive protein (CRP)   X c  X X   X  X  
Cardiac markers (Troponin I, 
CK)  X c  X X   X  X  
BNP  Xh,i X X X X X X X X X 
Complete blood count (CBC)   Xj,k X X X X X X X X X 
CBC differential   Xl,m X X X X X X X X X 
PT & INR   Xn,o X X X X X X  X  
Fibrinogen   Xp,q X X X X X X  X  
D-dimer   Xr,s X X X X X X X X X 
PaO 2/FiO [ADDRESS_424429] dose.   
Error! Reference source not found.  Patients who discontinue from study drug prior to recovery or prior to Day [ADDRESS_424430] a safety assessment 60 days after randomization .  
This will be in -person visit when possible or telephone follow -up.  
Study number:  S20-[ZIP_CODE]   Page 50 
Version: 1.1    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as aut horized in writing by [CONTACT_110810]: 11 January 2019  b Screening assessments conducted on the same day as randomization (Day 1) do not have to be repeated.   
c Performed pre -dose on Day 1.  
e A serum pregnancy test will be performed at th e Screening visit for WOCBP or at any point in time if a pregnancy is suspected.  Additional pregnancy assessments 
will be performed more frequently if required by [CONTACT_342678]/ECs.   
Error! Reference source not found. AE assessments on Day [ADDRESS_424431] is available to meet the study’s inclusion criteria . 
j End of Treatment visit can occur on Day [ADDRESS_424432] a fo llow-up visit at  Day 29.  This will be in -person vi sit when possible 
or telephone follow -up. 
l Cytokines are to be reported if feasible per clinical care at local site.  
 